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 Evidence suggests that high nicotine dependence observed in schizophrenia is 
related to its core neuronal deficits such as abnormalities in neural synchronization 
and sensory gating. Some of these neuronal deficits are shown to mark schizophrenia 
liability, raising the possibility that the increased nicotine dependence in 
schizophrenia is related to its etiological factors.  This study sought to investigat  
mechanisms of increased vulnerability to smoking and nicotine dependence in 
schizophrenia. The individual and interacting effects of familial vulnerability factors, 
neurophysiological function, and resting cortical oscillatory activity (i.e. resting EEG 
power) were examined. The study sample was composed of four groups including 
outpatients with schizophrenia, first-degree relatives of patient index probands, 
healthy comparison control subjects from the community, and first-degree relatives of 
control probands. The resulting data demonstrated a pattern of more persistent 
nicotine use and greater dependence among those with schizophrenia relative to non-
psychiatric comparison controls. Persistent smoking was also demonstrated to be 
  
highly heritable across groups with no discernable difference in the extent to which 
smoking is familial in those affected or unaffected by schizophrenia. With respect to 
resting oscillatory activity, analyses failed to find diagnostic group differences in 
EEG power for the alpha, beta, and gamma frequency bands and, unlike other 
substances of abuse, past and present nicotine use did not have a reliable effect on 
power in the beta frequency band. Rather, power in the gamma frequency band was 
significantly associated with smoking status. Furthermore, smoking was uniquely 
related to neurophysiological processes in probands with schizophrenia, suggesting 
that smoking status should be assessed in any study of information-processing 
dysfunction in this population. When all putative susceptibility factors were 
considered together, diagnosis of schizophrenia and family history of smoking best 
captured what may be characterized as an underlying (i.e. neurobiological) 
vulnerability to nicotine dependence, rather than circumscribed indices of 
electrophysiological functioning. Future studies might be implemented to refine the 
association between smoking and indices of electrophysiological function and, 
importantly, relate diagnostic or electrophysiological susceptibility factors to 
mediating processes and observable behaviors associated with aberrant patter s of 
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Chapter 1: Introduction 
Smoking and Nicotine Dependence in Schizophrenia 
 Prevalence 
Elevated rates of tobacco use and nicotine dependence in psychiatric 
populations are well-established research findings (Hughes, Hatsukami, Mitchell, and 
Dahlgren, 1986; Foulds, 1999). Moreover, prevalence of smoking among individuals 
diagnosed with schizophrenia is particularly high, with smoking rates reported 
between 70 and 90% (Diwan, Castine, Pomerleau, Meador-Woodruff, & Dalack et 
al., 1998; Glassman, 1993; Glynn & Sussman, 1990; Goff, Henderson, & Amico, 
1992; Hughes et al, 1986; Kelly & McCreadie, 1999; de Leon, Dadvand, Canuso, 
White, Stanilla, & Simpson, 1995; Llerena, la Rubia, Penas-Lledo, Diaz, & de Leon, 
2003; Worthington, Fava, Agustin, Alpert, Nierenberg, & Pava, et al., 1996; Ziedonis, 
Kosten, Glazer, & Frances, 1994), in contrast to the prevalence rate for smoking in 
the general population, estimated at 22.5% (Lasser, Boyd, Woolhandler, 
Himmelstein, McCormick, & Bor, 2000; Lethbridge-Cejku, Schiller, & Bernadel, 
2004). Smoking among individuals with schizophrenia poses a significant health risk 
to this population. Evidence suggests a two-fold increase in mortality rates due to 
smoking related diseases (e.g. lung cancer, circulatory and respiratory diseases, risk 
of cardiovascular disease) directly associated with lifetime tobacc use in patients 
with schizophrenia compared to the general population (Brown, Inskip, & 
Barraclough, 2000; Curkendall, Mo, Glasser, Rose, Stang, & Jones, 2004; Goff, 




epidemiological findings of elevated rates of smoking and further motivated by the 
significance of the consequent health implications, a large literature has developed to 
characterize and examine the association between nicotine use and schizophrenia.  
Examination of factors associated with smoking habits among those with 
schizophrenia has aimed to distinguish whether smoking in this population is a 
primary characteristic associated with the illness, or secondary to illness-related 
factors such as symptoms, chronicity of illness, or medication. Empirical evidence 
suggests that increased rates of smoking appear to be independent of socio-
demographic risk factors such as age, gender, race, or socioeconomic status (Diwan et 
al., 1998; Hughes et al., 1986; de Leon, Tracy, McCann, McGrory, & Diaz, 2002b). 
According to self-report, motivational factors behind smoking appear to be similar 
among smokers in the general population and smokers with mental illnesses including 
schizophrenia (e.g. relaxation, arousal) and thus do not account for the disparity in 
smoking prevalence rates (Glynn & Sussman, 1990). Furthermore, high rates of 
smoking among individuals with schizophrenia are not limited to inpatients or the 
chronically ill; elevated rates of smoking are found consistently among both 
inpatients and outpatients with schizophrenia (de Leon et al., 1995). In addition, 
hospitalized patients with schizophrenia, despite sharing environmental influences 
with patients affected by other illnesses (e.g. chronic mood disorders), comparatively 
demonstrate elevated smoking rates (de Leon, Diaz, Rogers, Browne, & Dinsmore, 
2002a). Smoking among patients with schizophrenia often appears to precede the 
onset of illness, prior to hospitalization (Kelly & McCreadie, 1999); smoking 




1992), and in first-episode patients with fewer than 30 day’s exposure to 
antipsychotic medications (McEvoy & Brown, 1999).  
 Phenomenology 
Increased rates of smoking among individuals with schizophrenia are not 
effectively explained by factors secondary to illness presentation or treatment. In 
addition to elevated prevalence rates of smoking, evidence suggests that 
schizophrenia patients are aberrantly heavy smokers, smoking a significant number of 
cigarettes per day (e.g. 25 or greater; Kelly & McCreadie 1999). Comparisons 
suggest that individuals with schizophrenia smoke a greater number of cigarettes per 
day than smokers in other psychiatric populations (de Leon et al., 1995) and smokers 
in the general population (Herran, de Santiago, Sandoya, Fernandez, Diez-Manrique, 
& Vazquez-Barquero, 2000). In addition, smokers with schizophrenia appear to 
exhibit unique smoking patterns, as given by observations of smoking cigarettes with 
greater nicotine content, smoking more of the cigarette (i.e. down to the filter), and 
inhaling more deeply than smokers without schizophrenia (Lohr & Flynn, 1992).  
Such behavioral observations have been further validated by quantitative data 
demonstrating that smokers with schizophrenia inhale with greater puff volumes, take 
a greater number of puffs per cigarette, and smoke with shorter inter-puff interval p  
cigarette than healthy comparison smokers (Tidey, Rohsenow, Kaplan, & Swift, 
2005); these measures together support the observations that individuals with 
schizophrenia exhibit smoking behaviors that are different and more “intense”. I  
addition to aberrant smoking behavior patterns, smokers with schizophrenia report 




et al., 2002b). Greater levels of nicotine dependence are coupled with a low desire to 
quit (Kelly & McCreadie, 1999), low spontaneous quit rates (de Leon, 1996), and 
unsuccessful structured quit attempts, with studies reporting 6 month abstinence rat s 
as low as 12% following smoking cessation programs (Addington, el-Guebaly, 
Campbell, Hodgins, & Addington, 1998; Zeidonis & George, 1997). This contrasts 
with successful quit rates of smokers from other populations whereby structured 
smoking cessation programs have resulted in quit rates upwards of approximately 
40% in smokers from the general population and between 18 and 32% in smokers 
with clinical mood disorders (Brown, Kahler, Niaura, Abrams, Sales, & Ramsey, et 
al., 2001; de Leon et al., 2002b). 
 Behavioral phenomenology suggesting abnormal smoking habits leading to 
greater nicotine intake are complemented by the findings from biological indexes of 
nicotine use in smokers with schizophrenia. Elevated blood plasma concentrations of 
nicotine and its metabolite cotinine have been reported irrespective of daily cig rette 
use, medication status, gender, severity of illness, or nicotine withdrawal time 
(Olincy, Young, & Freedman, 1997). Elevated levels of cotinine in smokers with 
schizophrenia in comparison to smokers in the general population is a finding that has 
been replicated and further investigated in other research groups as well. Williams 
and colleagues provided evidence for increased nicotine and cotinine levels in 
smokers with schizophrenia (Williams, Ziedonis, Abanyie, Steinberg, Foulds, and 
Benowitz, 2005); levels of cotinine were not related to other markers of enzymatic 
activity, suggesting that nicotine inhalation and absorption, not rates of nicotine 




authors reported little overlap between enzymes involved in nicotine and medication 
metabolism as well as a similar ratio of nicotine metabolites in patients and controls, 
all together suggesting that antipsychotic medications likely have no substantial effect 
on nicotine metabolism and nicotine or cotinine concentration in blood plasma 
(Williams et al., 2005). Finally, characteristics of smoking behavior, such as gre ter 
puff volume, faster rate of smoking, and longer cigarette smoking duration, appear to 
be related to higher blood nicotine levels among patients with schizophrenia 
compared to non-psychiatric smokers in the general population (Bridges, Combs, 
Humble, Turbek, Rehm, & Haley, 1990). Altogether, these findings suggest that such 
characteristics of smoking behaviors among those with schizophrenia may be 
clinically meaningful. 
Vulnerability to Nicotine Use 
 Molecular Links to Nicotine Systems 
Phenomenological, biological, and behavioral observations of smoking and 
nicotine dependence have elicited the development and investigation of multiple 
hypotheses in explaining the link between smoking and schizophrenia. Smoking and 
nicotine dependence in this population is not sufficiently explained by demographic 
factors, medication status, or concomitant use of alcohol or other substances. Rather, 
neurobiological abnormalities found in schizophrenia have demonstrated compelling 
linkages to nicotinic and other neurotransmitter systems in the brain.  
Evidence in post-mortem brain tissue indicates that schizophrenia is 




nicotinic acetylcholine receptors, apart from generalized loss of cell density; 
decreased receptor expression appears to be unrelated to smoking behavior (Court, 
Spurden, Lloyd, McKeith, Ballard, & Cairns, et al., 1999; Freedman, Hall, Adler, & 
Leonard, 1995). Tobacco smoking, known to increase high affinity nicotinic 
acetylcholine receptor binding sites in healthy smokers in a dose-dependent manner, 
fails to result in receptor upregulation in smokers with schizophrenia (Breese, Marks, 
Logel, Adams, & Sullivan, et al., 1997; Breese, Lee, Adams, Sullivan, & Logel, et al., 
2000). Both basal levels of nicotine receptors and mechanisms of up-regulation could 
contribute to individual differences in sensitivity to reward, persistence of smoking 
behavior, and severity of nicotine addiction (Collins, 1990). Abnormalities in neural 
nicotine receptor functioning might thus be integral to the understanding of smoking 
patterns and nicotine dependence in schizophrenia.  
The downstream effects of nicotine on other neurotransmitter systems may 
provide further insight into how smokers with schizophrenia may be differentiated 
from smokers in the general population. Studies of the effects of nicotine on 
glutamatergic functioning have yielded particularly intriguing findings. The 
expression of gene groups related to the glutamatergic N-methyl-D-aspartate 
(NMDA) postsynaptic density is recently shown to be disparately regulated by 
smoking in individuals with schizophrenia. Among individuals with schizophrenia, 
aberrantly low expression of genes encoding for postsynaptic NMDA receptors 
appears to be upregulated and normalized by smoking to levels found in non-
psychiatric controls (Mexal, Frank, Berger, Adams, & Ross, et al., 2005). Molecular 




schizophrenia, may therefore constitute a pathophysiological abnormality associated 
with the illness. Findings that gene expression is differentially altered with smoking, 
uniquely in schizophrenia, suggests that changes in glutamatergic excitatory 
neurotransmission may contribute to the development of nicotine addiction in this 
population (Mexal et al., 2005). Thus, the relationship between nicotine and the 
glutamatergic system in schizophrenia provides additional insight into how smoking 
has functional relevance in this population at the molecular level.  
 Cognitive and Neurophysiological Links to Nicotine 
In addition to linkages between nicotinic and other neurotransmitter systems, 
compelling links have been demonstrated between α7 icotinic cholinergic receptors 
and observable schizophrenia-related phenomenology including deficits in cognitive 
and neurophysiological functions. For example, laboratory administration of nicotine 
transiently improves cognitive deficits, such as in attention and working memory. In 
nicotine challenge studies, cognitive performance is  differentially affected by 
nicotine  administration such that participants with schizophrenia  shower greater 
improvement on  tasks than non-psychiatric controls (Depatie, O’Driscoll, Holahan, 
Atkinson, Thavundayil, & Kin, et al., 2002; George, Vessicchio, Termine, Sahady, 
Head, & Pepper, et al., 2002; Rezvani & Levin, 2001). Such differential effects 
appear unrelated to baseline differences in smoking (e.g. time since last cigare te). 
Cognitive deficits in attention, symptoms associated with schizophrenia such as 
thought disorder, auditory hallucinations, and experiences of sensory overload may 
all be associated with disrupted neurophysiological function (Leonard, Adler, 




Eisen, & Goldberg, et al., 2002; Williams & Ziedonis, 2004).  Neurophysiology 
generally describes how the brain processes sensory information and how this 
information is used to guide behavior. The links between neurophysiological 
functions, as studied in laboratory paradigms, and neural nicotine systems have been 
well studied. This linkage is exemplified by the study of impaired sensory gating.  
It is speculated that impaired sensory gating, the inability to accurately or 
efficiently process sensory information, may reflect a state of neuronal hyperarousal, 
in which neurons are hyperexcitable and thus oversensitive to sensory input. Defects 
in inhibitory neural pathways may underlie such abnormalities. As a result, neurons 
are unable to respond differentially to various inputs (Adler, Pachtman, Franks, 
Pecevich, Waldo, & Freedman, 1982; Braff & Geyer, 1990). While a vast array of 
neurophysiological abnormalities are observed in schizophrenia, the 
electrophysiological P50 auditory sensory gating response is a widely used laboratory 
measure for testing the integrity of inhibitory circuits (Braff & Geyer, 1990; see 
Methodology section for further discussion of the P50 paradigm). Adler, Hoffer, 
Wiser, & Freedman (1993) localized the neural response to repeated sensory 
stimulation, represented by the P50 waveform, to originate in and near the 
hippocampus. Thus, in effect, the P50 gating phenomenon represents the ability of the 
hippocampus to filter out extraneous background information and to focus attention 
on newer, more salient stimuli (Adler et al., 1993).  
Evidence suggests that the P50 sensory gating mechanism is mediated by 
nicotinic receptors on inhibitory interneurons located in the hippocampus and 




demonstrate relationships with genetic liability for schizophrenia (Waldo, A ler, 
Leonard, Olincy, Ross, & Harris, et al., 2000). This conclusion has been supported by 
the co-distribution of sensory gating deficits and schizophrenia in multi-affected 
families (Waldo, Carey, Myles-Worsley, Cawthra, Adler, & Nagamoto, et al., 1991) 
and genetic linkage analyses, which have demonstrated that deficits in sensory gating 
are associated with chromosome 15q13-14, the site of the α7-nicotinic acetylcholine 
receptor subunit gene (CHRNA7; Freedman, Coon, Myles-Worsley, Orr-Urtreger, & 
Olincy, 1997). More specifically, the peak linkage locus for the human P50 deficit is 
found at CHRNA7 gene marker D15S1360, which is shown to co-segregate with 
auditory gating deficits in family linkage studies of schizophrenia patients (Freedman 
et al., 1997). Further genotyping of this marker has revealed significant differences in 
allelic distributions for smokers and non-smokers with schizophrenia (De Luca, 
Wong, Muller, Wong, Tyndale, & Kennedy et al., 2004) while no such differences in 
allelic distributions have been reported in studies of smokers from the general 
population (Stassen, Bridler, Hagele, Hergersberg, Mehmann, & Schinzel et al., 
2000). These findings in particular may implicate a role of the nicotine receptor gene 
polymorphism in the pathogenesis of nicotine addiction in this patient population.  
Like cognitive deficits in memory and attention, nicotine has been shown to 
improve deficits in auditory sensory gating (P50) among individuals with 
schizophrenia (Adler et al., 1993). Additionally, smoking in a laboratory setting has 
been shown to have differential effects on auditory sensory gating between patients 
with schizophrenia and non-psychiatric controls, with a positive correlation between 




Freedman (1992) demonstrated similar remediation of P50 gating deficits with oral 
nicotine administration in relatives of individuals with schizophrenia who had 
diminished gating of the P50 wave.  
The link between neurophysiological dysfunction and neural nicotine systems 
is further illustrated by studies of eye movement deficits in schizophrenia. 
Oculomotor dysfunction is closely tied to neuropharmacological mechanisms 
associated with neuronal nicotinic receptors. Several eye tracking abnormalities (e.g. 
deficits in peak gain, eye acceleration during initiation of smooth pursuit response, 
antisaccade eye movement errors) have been shown to be temporarily corrected by 
laboratory nicotine administration (Depatie, et al., 2002; Sherr, Myers, Avila, Elliot, 
Blaxton & Thaker, 2002). In addition, the findings of several studies have converged 
in demonstrating a relationship between nicotine receptor functioning and saccade 
performance with smoking, nicotine, and nicotine agonists (e.g. ketamine) improving 
the number of leading saccade eye movements during visual tracking (Avila, Hong, & 
Thaker, 2002; Avila, Sherr, Hong, Myers, & Thaker, 2003; George, Verrico, 
Picciotto, & Roth, 2000; Olincy, Ross, Young, Roath, & Freedman, 1998). Taken all 
together, findings from a variety of research domains converge on the importance of 
nicotinic receptors in the pathophysiology of schizophrenia, and suggest that nicotine 
may serve a functional role for individuals with schizophrenia who smoke.  
The Self-Medication Hypothesis of Smoking and Schizophrenia 
Patterns of nicotine use do not support a self-medication hypothesis whereby 
pharmacological agents are utilized to alleviate positive or negative symptoms 




alternative hypothesis that the high smoking prevalence rate and the patterns of 
smoking behavior may represent an effort to remediate neurobiological dysfunctions 
associated with pathophysiological processes that characterize the disease. That is, 
nicotine administration via tobacco use may temporarily restore altered nicotinic 
receptor functioning, leading to improved neurophysiological and  cognitive 
functioning among individuals with schizophrenia. Thus nicotine use and dependence 
in this population appears to have a unique relationship, among substances of abuse, 
in linking defects in inhibitory neural pathways to smoking behaviors in individuals 
with schizophrenia. In sum, the self-medication hypothesis of smoking and 
schizophrenia postulates that smoking is a means of correcting an inherent neural 
abnormality, leading to improvements in information processing functions.   
 Low affinity nicotine receptors (α7) appear to play an integral role in 
facilitating proper inhibitory functions and nicotine administration tends to correct 
information processing functions that are otherwise deficient in schizophrenia. 
Sensory gating and eye tracking dysfunctions represent one manifestation of deficient 
information processing via cortical-subcortical pathways. The self-medication 
hypothesis posits that a relationship exists between smoking and schizophrenia 
through remediation of nicotine receptor function and transient remediation of such 
information processing deficits. However, neural inhibitory dysfunction may have 
multiple sources and may stem from an interplay between neurobiological pathways.  
 The link between schizophrenia and nicotine use may operate through 
mechanisms other than, or in addition to, the remediation of specific nicotine receptor 




nicotine use and schizophrenia is mediated through inhibitory neural circuitry 
dysfunction. For example, there is considerable evidence that α7 nicotinic 
acetylcholine receptors and receptors for the inhibitory neurotransmitter GABA 
coexist and are functionally related (Breese et al., 1997). Furthermore, an array of 
impairments in functions requiring cognitive control and inhibition of sensory-driven 
processes have been documented in schizophrenia, even beyond those described 
above (e.g. deficits in attention shifting, competitive response selection, saccadic eye 
movement, executive control necessary for working memory), suggesting the 
presence of a common disinhibitory neural mechanism (Curtis, Calkin, Grove, Feil, &
Iacono, 2001; Lewis, Hashimoto, & Volk, 2005). Thus, instead of focusing narrowly 
on the relationship between specific cognitive or neurophysiological functions and 
neural nicotinic systems, nicotine dependence in schizophrenia may be examined in 
relation to integrated neural network activity.  
An Alternative Electrophysiological Approach to Studying Nicotine Use in 
Schizophrenia 
 Pathophysiological Perspective on Smoking and Schizophrenia 
 The link between smoking and schizophrenia may be conceptualized from a 
pathophysiological perspective whereby neurobiological aspects of the illness 
contribute to nicotine use and dependence. The self-medication hypothesis postulates 
that a propensity towards nicotine use and an increased risk of dependence among 
individuals with schizophrenia  is associated with the remediating effects of nicotine 




schizophrenia pathology are increasingly focused on the study of dysfunctional neur  
circuitry rather than the functioning of specific brain areas or neurotransmitter 
systems. Characteristics of cortical brain functioning, such as the temporal dynamics 
of neural interactions, form the basis for lower level information processing, sesory 
integration, regulating consciousness, and for governing higher-order cognitive 
functions, as well as coordinating purposeful behavior (Begleiter & Porjesz, 2006; 
von Stein & Sarnthein, 2000). Thus, electrophysiological methodology assessing the 
integrity of integrated neural networks provides a unique perspective from which to 
approach the study of mechanisms underlying sensory, perceptual, and cognitive 
deficits associated with schizophrenia, and may inform processes underlying 
behavioral phenomena exhibited by those affected with the illness. If elevated rates of 
smoking and nicotine dependence are a function of schizophrenia pathophysiology 
(i.e. nicotine receptor and/or inhibitory circuitry dysfunction), then further 
examination of potential electrophysiological underpinnings may help to elucidate the 
mechanisms linking the pathophysiology of schizophrenia to smoking. The self-
medication hypothesis of smoking and schizophrenia may thus shift from examining 
the relationship between specific neurophysiological functions and nicotine to the 
relationship between nicotine and neural system activity.  
The study of brain oscillatory activity across the frequency spectrum is a tool 
that has been used to investigate cortical pathologies underlying other psychiatric 
conditions. Examining electrophysiological oscillatory activity is a mens of 
assessing the functional integrity of neural circuitry, including inhibitory neural 




behavioral phenomena may be used to expand current neuroscientific and 
psychological knowledge and theory of brain-behavior relationships. One such area 
of study that appears promising in linking nicotine use and dependence to 
schizophrenia is the quantification of beta power in resting EEG. Research from 
Begleiter and Porjesz (1999) has resulted in the supposition that elevated beta power 
represents a state of neuronal imbalance between excitatory and inhibitory inputs,
which has significant behavioral consequences. Studies of EEG functions in non-
schizophrenia populations implicate the unique role of cortical activity in the beta 
frequency band to vulnerability for alcohol and other substance use. However, 
delineation of functional linkages between beta power and nicotine use have largely 
been hampered by confounding comorbidity with other substance use in research 
samples. Furthermore, the overt behavioral significance of neuronal hyperexcitability 
or deficient inhibitory circuitry in schizophrenia remains unclear.  
 This study aims to address these gaps in the literature by clarifying the atur  
of the linkage between beta power in resting EEG and nicotine, and to characterize 
the role that this linkage might play in investigating nicotine use in the schizophrenia 
population. Drawing from a range of empirical findings in the schizophrenia, 
addictions, and neurophysiological literatures, a relationship between nicotine use and 
cortical dysregulation in schizophrenia may be hypothesized. Investigation of these 
relationships builds upon the self-medication hypothesis in linking neural 
pathophysiology associated with schizophrenia to nicotine use. In the following 
sections, the methodology of quantifying oscillatory activity ascertained from resting 




schizophrenia. The proposed significance of examining resting EEG in the beta 
frequency band will be discussed with respect to the findings in the alcohol and 
substance use literatures. Finally, a working model relating electrophysi logy, 
smoking, and schizophrenia will be discussed in providing a context for the current 
study.  
Cortical Oscillatory Activity  
 At the neuronal and neuron network levels, rhythmic oscillations and 
synchronous activity in the electroencephalogram reflect the relative strength and 
balance of inhibitory and excitatory inputs arising from both intrinsic regulatory 
mechanisms as well as in response to external stimulation. The frequencies at which 
neural oscillations (i.e. voltage fluctuations) occur and their spatial and temporal 
consistency (i.e. coherence, synchrony) are informative with respect to brain 
mechanisms underlying sensory processing and behavior (Engel, Fries, & Singer, 
2001; Salinas & Sejnowski, 2001). As such, fluctuations in cortical excitability, with 
respect to shifts in oscillatory activity and the level of synchronous activity of 
distributed neural networks, serve to control incoming sensory information and prime 
or guide stimulus-evoked responses (Engel et al., 2001).  
Oscillatory activity may be characterized with respect to the activity across 
the frequency spectrum; categorization yields five primary frequency bands, from the 
slowest to fastest: delta (1.0-3.0 Hz), theta (3.5-7.5 Hz), alpha (8.0-11.5 Hz), beta 
(12.0-28.0 Hz), and gamma (28.5-50 Hz) (Begleiter & Porjesz, 2006). Analysis of the 
relationships between specific components of oscillatory activity and human behavior 




and pathophysiological conditions of the central nervous system (see Appendix A for 
further discussion of neural oscillations). EEG patterns have been studied extensiv ly 
using family and twin designs. The majority of EEG parameters studied are stable 
within individuals and are found to be more similar among biologically related 
individuals than among non-familial controls (Porjesz, Almasy, Edenberg, Wang, 
Chorlian, & Foroud, et al., 2002; Tang, Chorlian, Rangaswamy, O’Connor, & Taylor, 
et al., 2007).   
 Cortical Oscillatory Activity in Schizophrenia 
The study of EEG power, that is the amount of oscillatory activity in a given 
frequency band (e.g. delta, theta, alpha, beta, gamma), among individuals with 
schizophrenia may contribute to understanding mechanisms of neural network 
dysfunction and the mechanisms underlying observable sensory, perceptual, and 
cognitive deficits (Spencer, Nestor, Perlmutter, Niznikiewicz, & Klump, 2004; van 
der Stelt, Belger, & Lieberman, 2004). Thus, oscillatory activity in schizophrenia may 
also be informative in linking sensory processing with illness-related behavior, such 
as smoking. Although resting EEG is found to be consistent across family members in 
samples drawn from the general population, vulnerability to schizophrenia appears to 
be associated with wider ranging inter-individual variability in resting EEG function. 
EEG differences in monozygotic twins concordant and discordant for schizophrenia 
suggest both broad genetic and specific pathologically determined abnormalities in 
cortical functioning (Stassen, Coppola, Gottesman, Torrey, Kuny, & Rickler et al.,
1999). Variability in EEG parameters among schizophrenia co-twins is not 




for similar psychometric properties of resting EEG power (e.g. test-retest reliability) 
in schizophrenia and healthy populations (Lund, Sponheim, Iacono & Clementz, 
1995). Furthermore, frequency characteristics of EEG appear to be consistent in first-
episode and chronic schizophrenia patients with no identifiable effects of illness 
duration or chronic treatment (Sponheim, Clementz, Iacono, & Beiser, 1994).  
In the twin study by Stassen and colleagues (1999), schizophrenia probands 
and unaffected monozygotic co-twins were differentiated by a generalized pattern of 
increased low frequency theta and decreased alpha activity associated with illness 
manifestation.  Other quantitative comparisons of resting EEG anomalies between 
schizophrenia and healthy comparison subjects have reported similar findings of less 
alpha activity, more delta, theta, and beta activity; schizophrenia-related EEG 
abnormalities in the frequency domain have been described by principle components 
analysis as demonstrating a high proportion of fast activity, augmented low frequency 
activity, and diminished alpha band power (Clementz, Sponheim, Iacono & Beiser, 
1994; Kahn, Weiner, Coppola, Kudler, & Schultz, 1993; Sponheim et al., 1994).  
Examination of clinical and biological correlates of resting state EEG power 
has aimed to better characterize illness-related anomalies. Variations in resting EEG 
appear to be unrelated to duration of illness or treatment. Findings from Sponheim 
and colleagues (2000) replicated the coupling of augmented low frequency (delta and 
theta) power with diminished alpha power found in patients with schizophrenia as 
well as in individuals with non-schizophrenia psychosis. Though these EEG 
characteristics may represent generalized manifestations of cortical pathology, EEG 




by associations between abnormal EEG power and negative symptomatology, poorer 
ocular motor functioning, wider third ventricles, larger frontal horns of the latera  
ventricles, and larger cortical sulci in the schizophrenia patients (Sponheim, 
Clementz, Iacono & Beiser, 2000).  Both cortical and subcortical pathologies are 
suggested by the clinical and biological correlates of augmented lower frequency and 
diminished alpha band power in schizophrenia.  
Metabolic hypofrontality, structural frontal lobe and thalamic anomalies, and 
cortical disruption thus appear to be a constellation of findings representing a 
dysfunction of thalamic-cortical projections in schizophrenia. As ascertaind from 
measurements of cortical activity, lower levels of alpha activity may reflect atrophy 
of the thalamus, while higher theta activity may reflect hippocampal dysfunction 
(Stassen et al., 1999). Functionally, investigators have postulated that lower alpha and 
elevated beta activity together correspond to deficits in the modulation of attention 
and arousal (Kahn et al., 1993). Additional abnormalities in higher frequency gamma 
oscillatory activity may uniquely underlie other cognitive dysfunctions in 
schizophrenia, such as perceptual binding and working memory (Bramon, McDonald, 
Croft, Landau, Filbey, & Gruzelier et al., 2005). 
Gamma activity, unlike oscillatory activity in lower delta and theta frequency 
bands, appears to reflect a fundamental frequency critical for cortico-cortical 
communication, and is likely responsible for coherent neuronal functioning and, 
subsequently, integrated normal cognitive functioning (Rodriguez, George, Lachaux, 
Martinerie, Renault, & Varela, 1999). Investigated in normal subjects, gamma band 




processing of reward stimuli, as given by increasing frontal gamma activity dur ng an 
operant shaping paradigm (Keil, Muller, Gruber, Wienbruch, & Elbert, 2001). 
Investigation of reduced gamma band activity in schizophrenia has gained increasi g 
popularity in characterizing underlying neural network dysfunction and information 
processing deficits (Light, Hsu, Hsieh, Meyer-Gomes, Sprock, & Swerdlow et al.,
2006); the pathophysiological relevance of gamma activity is also supported by 
findings of lower stimulus- evoked gamma activity in first-degree relativ s of 
schizophrenia probands (Hong, Summerfelt, McMahon, Adami, Francis, & Elliott et 
al., 2004). Gamma band activity is viewed empirically as a ubiquitous mechanism 
underlying information processing and, due to the extent of sensory and cognitive 
integrative dysfunction in schizophrenia, is likely integral in affecting neural 
processing among affected individuals. In addition, reduced synchronous gamma 
activity has demonstrated unique associations with clinical symptoms of 
schizophrenia including thought disorder, visual hallucinations, and disorganization 
(Spencer et al., 2004). 
While the schizophrenia literature has substantiated findings of augmented 
low frequency power, diminished alpha activity, and reduced gamma band activity, 
much less research has sought to characterize aberrant oscillatory activit in he beta 
band.  Beta power has been discussed within the context of abnormal alpha power, as 
regulating arousal and attention, and beta activity has been coupled with gamma band 
oscillations in representing the coordinated activity of excitatory and inhibitory neural 
assemblies (Miller, 2007). Higher frequency oscillations within the beta band have 




(Strelets, Novototsky-Vlasov, & Golikova, 2002) in response to sensory stimuli. 
Given that inhibitory interneurons appear to be crucial in generating synchronous 
neural activity in the beta and gamma bands of the EEG (Whittington & Traub, 
2003), analysis of cortical activity in both frequency bands together is likelyint gral 
to understanding information processing in schizophrenia. Indeed, both beta and 
gamma band oscillations in healthy individuals have been shown to underlie deficits 
in sensory gating paradigms (Hong, Summerfelt, McMahon, Thaker, & Buchanan, 
2004).  
Dysregulation of neural circuit inhibition in schizophrenia is postulated to 
stem from dysfunctional thalamocortical circuitry, and/or aberrant inhibitory 
(GABAergic) interneuron or excitatory (glutamatergic) input. All areconsistent with 
evidence for lower neural synchrony and cortical hyperexcitability in schizophrenia 
(Hoffman & Cavus, 2002). Beta frequency oscillation is linked to cortical inhibitory 
function in schizophrenia, and has been shown to contribute uniquely to impaired P50 
gating. This unique contribution of beta oscillations to aberrant sensory gating may be 
more robust among individuals with schizophrenia than non-schizophrenia controls, 
although this finding requires replication (Hong et al., 2004). This study will address 
the relative lack of focus on oscillatory activity in the beta frequency band and its 
significance in schizophrenia by examining beta power in resting EEG in a 
schizophrenia sample.  
While the direct contribution of oscillatory activity to information processing 
deficits in schizophrenia is under study, beta oscillation in the electroencephalogram 




(Neidermeyer, 1999). As indicated in both the schizophrenia and normal literature, 
rhythmic activity of neural oscillations within the beta frequency band is con idered 
as an index of cortical excitation or arousal (Begleiter & Porjesz, 1999) and has been 
associated with multisensory integration and information processing (von Stein & 
Sarthein, 2000). Outside of the schizophrenia literature, studies of etiologic factors 
associated with addictions indicate a role for increased absolute beta power in resting 
EEG (Bauer, 1994; Costa & Bauer, 1997). Resting beta band power, as an index of 
baseline cortical excitation, may therefore represent a candidate measure for linking 
basic neural functional activity in schizophrenia to nicotine addiction. Hypotheses 
regarding the functional significance of resting beta band activity in schizophrenia 
may be generated by first considering the role of beta activity as  relates to 
substance use.   
The Significance of Beta Band Activity 
 Susceptibility to Alcohol Use 
Analysis of the relationships between specific components of oscillatory 
activity and human behavior may provide a basis for understanding underlying 
physiology and etiology of normal and pathological conditions of the central nervous 
system. Trait and state-like characteristics of cortical activity ma be predictive of 
liability toward the development or maintenance of specified pathologies. In 
particular, the alcohol use literature may be informative in examining neural network 
mechanisms associated with physiological as well as behavioral correlates of risk for, 
and expression of, substance dependence. Early support for elevated beta power 




large-scale collaborative study of the genetics of alcoholism. Absolute power spectra 
derived from resting EEG of alcohol dependent individuals has demonstrated 
consistent and significant increases in beta band oscillation relative to non-dependent 
controls, largely over frontal and central brain regions. Though findings tend to be 
more robust for males than females, beta band amplitudes were reportedly unaffected 
by characteristics of alcohol use (e.g. quantity or recency of drinking) or age 
(Rangaswamy, Porjesz, Chorlian, Wang, & Jones, & Bauer, 2002). The lack of 
significant relationship with alcohol use variables led the investigators to hypothesize 
that elevated beta band power is associated with the development, rather than a direct 
consequence of, alcohol misuse. 
Further analysis of beta band oscillations from resting EEG has demonstrated 
similar absolute power elevations in offspring of male alcoholics, relative to family 
history negative controls, regardless of their current alcohol use disorder diagnosis 
(Rangaswamy, Porjesz, Chorlian, Wang, Jones, & Kuperman, 2004). Though again, 
significant elevations in beta power were limited in females with a positive family 
history while beta power was significantly elevated across the beta frequency band in 
males, these findings are generally consistent with prior studies reporting higher beta 
power in the resting EEG of family history positive individuals. Such findings 
suggest that elevated beta power represents a trait- rather than state-rela ed correlate 
of alcohol dependence, and suggest that elevated beta power is more likely a 
precursor to than an effect of alcohol exposure. Furthermore, Rangaswamy et al. 




than males, indicating that gender differences within the beta range may be a marker 
for differential vulnerability in males and females.  
Additional characterization of oscillatory activity across the frequency 
spectrum has underscored the predictive power of increased beta band activity with 
respect to risk for substance use in general. Power analyses in remitted subsance 
(alcohol or drug) using individuals differentiated between abstinence- and relapse-
proneness by higher frequencies in the beta band of resting EEG (Bauer, 2001). 
Abnormal elevation in beta power did not vary with substance use problem severity, 
depression, or anxiety, and interactions between outcome and type of substance were 
non-significant. In addition, while outcome, family history of alcoholism, and 
childhood history of conduct disorder significantly interacted to predict current beta 
power elevation, logistic regression revealed that beta power was the only significant 
predictor of remission status over long term evaluation, such that higher beta power 
was associated with increased rates of relapse (Bauer, 2001). The findings from this 
study confirm the association between elevated beta power and risk for alcohol use, 
and suggest that, among those who have already initiated substance use, elevated beta 
power may be associated with risk for relapse. Furthermore, the findings from Bauer
(2001) extend the findings of previous studies by suggesting that abnormal elevation 
in beta power might be considered a general vulnerability factor, common to 
substances of misuse and dependence in addition to alcohol.   
Indeed, changes in brain activation are associated with other psychoactive 
substances and may describe alterations in cortical brain function associated with 




drug-induced increases in power spectra, particularly in the alpha and beta bands, in a 
laboratory setting. Drug-related changes in brain activation also include alter d 
cortical connectivity from alpha and beta generated neuronal networks over time 
(Fingelkurts, Fingelkurts, Kivisaari, Pekkonen, Ilmoniemi & Kahkonen, 2004; 
Herning, Glover, Koeppl, Phillips, & London, 1994; Jensen, Goel, Kopell, Pohja, 
Hari, & Ermentrout, 2005). The latter results are thought to indicate a restructuring of 
neuronal networks with continued drug use, which likely has implications for changes 
in higher order cognitive functions such as problem solving, set maintenance, set 
shifting, behavioral control (Fingelkurts, Fingelkurts, Kivisaari, Autti, Borisov, & 
Puuskari, et al., 2006) with drug use over time.  
 Complicating the interpretation of the former results is the significant but 
varied drug use histories of the participants, including past and current use of 
amphetamine, heroin, barbiturates, hallucinogens, marijuana, cocaine, alcohol, and 
nicotine. The varied histories of substances used in the past, in addition to recent 
substance use confound characterization of the specificity and temporal relationship 
with oscillatory activity. It is noteworthy, however, that similar changes in neural 
activity were obtained from drugs with both stimulant and depressant properties. This 
observation underscores the presupposition that neural mechanisms might be non-
specific, underlying vulnerability to substance use in general.  
With regard to the specificity and temporal relationship between substance use 
and beta band activity, in most studies alterations in beta power were not isolated t  
one substance, nor associated with specific substance use variables such as lengt or 




1994; Bauer, 2001, Costa & Bauer, 1997). Additional findings reporting on cortical 
activity in abstinent male heroin users suggest that increased EEG coherence1 of 
frequency activity (e.g. theta, low beta, and gamma frequency coherence) may be 
related to the direct effects of drug use, in contrast to elevated power in the beta band, 
which may better represent susceptibility to drug use (Franken, Stam, Hendriks, & 
van den Brink, 2004). These findings are consistent with those reporting the 
predictive relationship between beta power and relapse-proneness in abstinent 
individuals (Bauer, 2001), as well as the findings of elevated beta power in unaffected 
individuals with a positive family history of alcohol dependence (Rangaswamy et al.,
2004).   
Further support for spectral power as a trait indicator of susceptibility may be 
provided by genetic findings of a mean reported heritability estimate of 86% for beta 
power (Porjesz et al., 2002). Notably, the heritability of the beta frequency band of 
EEG is higher than heritability rates reported for alcohol dependence itself (49-64%; 
McGue, 1999), recommending such electrophysiological measures as beta power as a 
more proximal predictor of gene effects than the clinical diagnoses associated w th it. 
Such gene effects likely do not confer risk for use or dependence on any one 
substance in particular, but may impart vulnerability for other antecedents to 
substance use or addiction.     
Thus, empirical evidence supports a generalized risk for substance use or 
propensity towards addiction. Family, adoption, and twin studies support the familial 
aggregation of alcohol dependence and the importance of genetic factors in 
                                                
1 EEG coherence refers to the correlation between two signals measured at the same time; high 
coherence indicates a close functional coupling betwe n neuronal populations in different brain areas 




developing alcohol use disorders. The aggregation of substance use disorders in 
addition to alcohol in relatives of alcohol dependent individuals has also been 
reported, whereby the increased risk for substance dependence in relatives (e.g. 
marijuana, cocaine, tobacco) is only partly independent of familial alcohol 
dependence (Bierut, Dinwiddie, Begleiter, Crowe, Hesselbrock, & Nurnberger, et al., 
1998; Nurnberger, Wiegand, Bucholz, O’Connor, Meyer, & Reich, et al., 2004). Such 
data are consistent with specific causative factors in developing types of substance 
dependence and common addictive risk factors for substance use in general.  
Begleiter and Porjesz (1999) theorize that a genetic predisposition to develop 
substance dependence is signified by a disequilibrium in homeostatic mechanisms 
controlling the balance between excitation and inhibition in the central nervous 
system. Individuals with an imbalance in disinhibition/hyperexcitability home static 
mechanisms may be particularly sensitive to the effects of substances of misuse, 
including alcohol and other drugs, affecting substance use initiation as well as 
continued substance use (Begleiter & Porjesz, 1999). Beta power as been identified as 
an electrophysiological marker for this imbalance, conferring vulnerability for 
substance use and dependence (see Appendix A for further discussion). Although beta 
power can be measured over most scalp regions in EEG, beta power measured in 
frontocentral and centroparietal regions tend to best differentiate individuals with and 
without alcohol use disorders (Rangaswamy et al., 2002). The source of resting beta 
oscillatory activity, however, has been localized to the frontal lobe of the brain, a 
region known to be important to behavioral control (Bauer, 2001). A frontal source 




been suggested by abnormalities in brain wave amplitudes measured in response to 
external stimuli (i.e. event related potential deficits). A deficiency in the P300 event 
related component, a positive fluctuation in brain wave amplitude measured 300 ms 
following a stimulus event, has demonstrated associations with liability to the 
development (Rangaswamy, Jones, Porjesz, Chorlian, & Padmanabhapillai, et al., 
2007) and risk for relapse of alcohol and drug use (Bauer, 1997).  
The low amplitude P300 component has been touted as a putative phenotypic 
marker of risk for developing alcohol dependence, supported by evidence from family 
and longitudinal study designs (Begleiter & Porjesz, 1999). Poor P300 response is 
associated on behavioral tasks with an undifferentiated mode of responding to 
incoming visual or auditory stimuli, thereby suggesting an electrophysiologica  
problem of cognitive and behavioral disinhibition in alcohol dependent and well as in 
at-risk individuals (Begleiter & Porjesz, 1999). Poor P300 response is predictive of 
other disorders, such as attention deficit hyperactivity disorder and antisocial 
personality disorder. Thus P300 performance deficits, like elevated beta power, 
represent a mechanism of neural disinhibition associated with both cognitive and 
behavioral consequences, including significant psychopathology (Moeller Barratt, 
Dougherty, Schmitz, & Swann, 2001). Given the relationship between poor P300 
response, poor information processing, and clinical disorders characterized by 
disinhibition, it is interesting to note that impairment in the P50 gating response, 
another electrophysiological measures of neuronal inhibitory processing, has been 
documented with respect to substance use disorders such as cocaine and alcohol 




Marco, Fuentemilla, & Grau, 2005).  Furthermore, poor P300 response and P50 
gating deficits have both been well documented among those with schizophrenia and 
their relatives (Bramon, et al., 2005).  Thus, multiple neurophysiological, cognitive, 
and behavioral outcomes may be characterized by an underlying cortical 
disinhibition/hyperexcitability. This neural network disinhibition may relat  
etiologically to a number of disorders, including schizophrenia.  Yet, the 
methodology utilized by Begleiter and Porjesz (1999) to characterize this cortical 
hyperexcitability has not been applied to schizophrenia. In a population characterized 
by significant rates of substance use and even higher rates of nicotine use, this 
electrophysiological mechanism may have significant explanatory power (se  
Appendix A for further discussion of neural network disinhibition and schizophrenia).  
Substance Use and Smoking in Schizophrenia 
Further study of overlapping neurobiological deficits and behavioral 
characteristics of disorders is likely to be informative in elucidating the etiology, 
pathophysiology, and in understanding the phenomenology of various psychiatric 
conditions.  Within the schizophrenia population, consideration of variables 
contributing to susceptibility for nicotine use and cigarette smoking might include 
those that overlap with substance use disorders. It is known that schizophrenia is 
commonly comorbid with substance use disorders, with lifetime prevalence rates 
estimated between 40 and 50% (Blanchard, Brown, Horan & Sherwood, 2000). As 
indicated, rates of nicotine use in schizophrenia are estimated in the range of 70 to 
90%. In neither case is substance use predicted by overt illness symptomatology; 




alcohol, drug, or nicotine use than qualities of present illness manifestation 
(Blanchard et al., 2000). By briefly examining alcohol and substance use within the 
schizophrenia population, mechanisms of vulnerability to dependence overlapping 
with nicotine use may be hypothesized.  
A relationship between substance use and brain reward circuitry dysfunction 
in schizophrenia may have some explanatory power with respect to the increased 
sensitivity to the effects of substances. For example, enhanced positive subjective 
response to substances has been reported with alcohol, which produces greater 
euphoria and stimulatory effects among individuals with schizophrenia than non-
schizophrenia controls (D’Souza, Gil, Madonick, Perry, Forseliu-Bielen, & Braley, et 
al., 2006); the degree of subjective response may be a substantial contributor to the 
risk for substance use initiation, continued use, and the development of dependence.  
Likewise, individuals with schizophrenia may be more vulnerable to the effects of 
nicotine such that nicotine may be a stronger reinforcer, compared to smokers without 
schizophrenia, due to neurobiological substrates associated with the disorder itself 
(Chambers, Krystal & Self, 2001). According to Begleiter and Porjesz (1999), 
increased sensitivity to substances of misuse may also be a consequence of an 
imbalance in cortical excitation and inhibition, thus conferring greater risk for 
substance dependence.  
Neurobiological substrates associated with substance use have been examined 
with respect to cognitive performance deficits as they may relate to poor behavioral 
control in schizophrenia. On cognitive or neuropsychological tests, patients with 




general; poorer executive functioning may translate behaviorally into reward 
sensitivity as suggested above, impulsive behavior, and/or lack of response to 
environmental contingencies, all of which may be related to continued substance use. 
However, the extent to which cognitive performance data support a specific cognitive 
control problem differentiating schizophrenia patients with or without a substance use 
disorder is limited (Thoma, Wiebel, & Daum, 2007). It is unclear whether the 
sensitivity or specificity of cognitive performance measures may obscure important 
findings. Therefore, other assessments of brain function associated with substance use 
disorders may provide a more parsimonious link between upstream neurobiological 
dysfunction and downstream complex behaviors. Gating of sensory information (i.e. 
P50 response) appears to represent one of those linkages. Yet again, from a broader 
perspective, examination of cortical processes related to neurophysiological 
impairment and predisposing to substance use may have more promising implications 
for understanding the phenomenology of smoking and nicotine dependence in 
schizophrenia. As cortical oscillatory activity in the beta band has been shown to 
relate to sensory gating performance, elevated beta power may represent an 
alternative, but related, mechanism of nicotine use in schizophrenia, complementing 
the self-medication hypothesis as it pertains to disinhibitory information processing 
dysfunction.  
As presented in this review, vulnerability to nicotine use in schizophrenia may 
be conceptualized from a pathophysiological perspective whereby broad and specific 
factors associated with the illness may lead to nicotine use and dependence. 




predispose individuals affected by the illness to addiction in general. Specific 
molecular aspects such as aberrant nicotine receptor expression, regulation, or 
nicotine induced neural activity may confer vulnerability to nicotine use and 
dependence as well. Broad and specific factors are likely not mutually exclusive, as 
nicotine and nicotine receptor functions interact with other neurochemical system  
(e.g. glutamate, GABA, dopamine) among various neural circuits integral to 
processing of incoming sensory information and guiding observable behaviors. 
Vulnerability to nicotine addiction, in both the broad and specific sense, is further 
illustrated by consideration of genetic contributions, which likely encompass any 
number of neurobiological or behavioral functional relationships discussed above.  
 Genetic Contributions to Nicotine Use 
As studied in the general population, susceptibility to smoking initiation and 
nicotine dependence are influenced by a number of individual difference and 
environmental factors. Genetic evidence from non-schizophrenia populations 
suggests that factors conferring risk for nicotine use may overlap with those 
conferring risk for other substance use. Data from family studies and genetic linkage 
analyses have concluded that both specific and common genetic factors are integral n 
the development of habitual smoking and alcohol dependence (Bierut et al., 2004). 
However, the genes or gene products that confer a specific or general vulnerability to 
substance use and progression to dependence have yet to be deciphered.  
With regard to nicotine use, total heritability estimates for initiation and 
progression to nicotine dependence are approximately 60 to 70% (Kendler, Neale, 




Scherrer, Waterman, Goldberg, Lin, et al., 1997). In addition, several aspects of 
smoking behavior such as initiation, persistent smoking, and level of nicotine 
dependence each have been found to cluster in families (Bierut, Rice, Goate, 
Hinrichs, Saccone, & Foroud, et al., 2004). A substantial collection of data from 
family as well as twin and adoption studies converge in reporting combined genetic 
(~60%) and environmental (~20% shared, ~20% unshared) influences on smoking 
initiation, but relatively negligible effects of environment compared to a significa t 
genetic (~70%) contribution to progression to nicotine dependence (Sullivan & 
Kendler, 1999). That progression to nicotine dependence, as opposed to smoking 
initiation, is predicted more robustly by genetic factors may reflect th  presence of 
specific genetic mechanisms of addiction related to nicotine use than to substance use 
in general.  
Given that genetic liability for schizophrenia has been clearly demonstrated by 
the results of family, twin, and adoption studies (McGue & Gottesman, 1989; Tsuang 
& Faraone, 1994), and that additional evidence supports elevated rates of nicotine 
mediated neurophysiological dysfunction in unaffected relatives, a plausible 
hypothesis is that elevated rates of nicotine use would be observable in family 
members of individuals with schizophrenia as well. Evidence from Lyons and 
colleagues (2002) do indicate elevated rates of nicotine dependence as well as 
unsuccessful smoking quit attempts among unaffected co-twins of patients with 
schizophrenia, providing preliminary support for this hypothesis. However, the extant
literature has yet to identify which elements of genetically mediated ndividual 




dependence. Speculation as to the mechanism of the genetic effect on nicotine 
dependence promotes further study with regard to molecular influences on 
pharmacokinetics and pharmacodynamics governing the activity of bioavailable 
nicotine, neurotransmitter systems involved in nicotine intake, as well as other 
individual difference factors conferring risk for nicotine addiction (Bierut et al., 2004; 
Sullivan & Kendler, 1999; Yoshimasu & Kiyohara, 2003).  In considering the range 
of specific factors contributing to vulnerability to nicotine dependence, this study will 
aim to first describe the heritability of nicotine dependence associated with genetic 
predisposition to schizophrenia, thereby laying the groundwork for more molecular 
investigations in the future.  
Building a Working Model of Smoking and Schizophrenia 
A baseline imbalance in homeostatic mechanisms regulating excitatory and 
inhibitory cortical activity may confer susceptibility to addiction. Given the robust 
literature on neural inhibitory dysfunction associated with vulnerability to substance 
use disorders, schizophrenia, as well as the frequent comorbidity of substance use 
with schizophrenia, consideration of Begleiter & Porjesz’s (1999) cortical 
disinhibition/hyperexcitability hypothesis of trait susceptibility to alcohol dependence 
may have implications for susceptibility to addiction in the schizophrenia population. 
Elevated resting oscillatory activity in the beta band likely reflects this trait-like 
condition of cortical dysregulation. Empirical evidence supports elevated beta power 
in frontal and central brain regions as a significant predictor of substance use and 
dependence without apparent specificity for drug type or inherent drug effect. In 




use of alcohol or other drugs often overshadows an explicit focus on nicotine use or 
confounds study findings. Yet, nicotine is arguably the most addictive substance and 
the most commonly used; higher levels of nicotine use are also found in psychiatric 
populations among whom electrophysiological abnormalities are evident. A clinically 
meaningful link between nicotine and neurobiological dysfunction is suggested by 
these findings.  
Nicotine use has been shown to have a unique relationship with vulnerability 
to schizophrenia. As such, nicotine has received attention as a substance of use in its 
own right, yet there is an apparent lack of both specificity in, and clear integration 
with the literature on alcohol and other substance use. Examining patterns of 
electrophysiological activity, which have previously demonstrated linkages with 
susceptibility to alcohol and other substance use disorders, with respect to nicotine 
use may ultimately be informative in proposing mechanisms by which vulnerability 
for nicotine dependence may manifest in those affected by the illness.  
The self-medication hypothesis proposes that smoking and nicotine use in 
schizophrenia represents an effort to remediate basic information processing deficits 
that characterize the disease and are associated with disease vulnerability. 
Information processing dysfunctions intimately tied in the schizophrenia liter tur  to 
nicotine use and genetic liability include those which rely on frontal cortical function, 
thalamocortical circuits, and overall inhibitory neural processing. These mechanisms 
may overlap with those conferring vulnerability to substance use disorders as studied 




This study thus aims to incorporate an array of methodologies to investigate 
mechanisms of increased vulnerability to smoking and nicotine dependence among 
individuals with schizophrenia. This study will approach this research problem from a 
perspective encompassing the individual and interactive effects of genetic 




Chapter 2: The Current Study 
Rationale 
A linkage between smoking and schizophrenia may be conceptualized from a 
pathophysiological perspective, such that aspects of the neuropathology of the illness 
confer vulnerability to addiction, particularly to nicotine. At a molecular level and at 
a behavioral level, nicotine use may serve a clinical or functional purpose for those 
affected by the illness. The current study aims to further investigate the self-
medication hypothesis of smoking in schizophrenia, which purports that smoking 
behaviors and high rates of nicotine dependence represent an effort to remediate 
underlying information processing deficits associated with neurophysiologica  
underpinnings of illness vulnerability. Nicotine use has previously been studied in the 
context of sensory gating and ocular motor dysfunctions, which are thought to 
represent observable effects downstream of genetic liability to schizophrenia. This 
study proposes to approach nicotine use and information processing in schizophrenia 
from a complementary perspective, that of aberrant brain oscillatory activity as 
assessed with EEG. Cortical oscillatory activity has been shown to underlie such 
performance deficits.  
This study proposes to examine whether the predictive utility of elevated beta 
power may be extended from predicting alcohol use and dependence to a propensity 
towards nicotine use, and whether this mechanism also holds explanatory power in 
linking smoking and elevated nicotine dependence to schizophrenia. The current 




probands and their first-degree relatives, in a between groups design to examine 
multi-level study aims. Data were extracted from semi-structured diagnostic and 
family history interviews, a self-report questionnaire of nicotine use, and laboratory 
paradigms to assess sensory gating (P50) and to analyze spectral power in resting 
EEG. Research hypotheses were formulated according to three broad study aims, first 
to examine the effect of a family history of schizophrenia on the heritability of 
nicotine use and dependence, second to examine the relationship between oscillatory 
activity in the beta band and nicotine use, and third, to examine relationship among 
variables in predicting nicotine use and dependence. This section will outline each 
study hypothesis and discuss additional factors that were considered in the study 
design and statistical analyses that followed data collection. 
Specific Study Aims and Hypotheses 
Specific Aim 1: Compare rates of smoking and heritability of smoking among 
individuals with and without a family history of schizophrenia. 
 Hypothesis 1a: Prevalence of nicotine use, past or present, will be greater 
among patients with schizophrenia than healthy comparison controls, and 
prevalence of smoking will be greater among first-degree relatives of 
schizophrenia probands than first-degree relatives of probands drawn from the 
general population.  
 Hypothesis 1b: Genetic contributions to nicotine use, as given by heritability 
estimates, will be greater among those family history positive for 




The first hypothesis broadly examines rates of nicotine use and the association 
between smoking and vulnerability for schizophrenia and aims to replicate previous 
reports of elevated smoking prevalence in this patient population. Second, data from 
family members of demographically matched community probands provide a 
comparison prevalence rate of smoking in the general population with which to 
examine the prevalence of smoking in those with a family history of schizophrenia. 
This comparison was proposed for descriptive purposes to document relative rates of 
smoking in family members, regardless of the smoking status of the index proband. 
The second hypothesis examines patterns of nicotine use in families, taking into 
account the smoking status of the schizophrenia or control proband and the degree of 
genetic relationship among family members (i.e. parent, sibling).    
Specific Aim 2: Examine the relationship between nicotine use and beta 
frequency activity in resting EEG.  
 Hypothesis 2a: Beta power will be elevated in those with a smoking history 
relative to those with no history of nicotine use.  
 Hypothesis 2b: Differences in cortical activity in the beta band between 
smokers and non-smokers will be greater among probands with schizophrenia 
than comparison controls.  
 Hypothesis 2c: A significant relationship between resting EEG spectral power 
and smoking history will be specific to beta activity as compared to power in 
the alpha and gamma frequency bands.   
The hypotheses associated with the second specific aim are based upon any history of 




compared to those without any history of smoking (“never-smoker”). Secondary 
analyses were proposed to examine differences between current, former, and non-
smokers without a priori hypotheses. In examining the relationship between beta 
power and smoking history, diagnosis was used as a between-groups factor to test the 
relationship between resting EEG and nicotine use in those with and without 
schizophrenia. This is specified in hypothesis 2b. A differential effect of smoking 
between patients and controls might indicate the extent to which electrophysiological 
functioning has significant utility in explaining smoking in schizophrenia. Given 
previous findings of the effects of gender in characterizing the relationship between 
beta power and alcohol dependence, gender was considered an additional factor in 
examining differences in resting EEG power.  Significant histories of past alcohol or 
drug use were also considered in the study design and in statistical analyses folowing 
data collection.  
Finally, hypothesis 2c aims to test the specificity of the relationship between 
nicotine use and electrophysiological activity in the beta band. Comparing 
relationships between nicotine use and activity across the frequency spectrum may 
provide insight as to whether smoking is related to a broad increase in cortical 
arousal, whereby elevations in power across the frequency spectrum would be 
expected, or whether distinct frequency bands are affected.  
Specific Aim 3: Investigate the relationships among variables hypothesized to 





 Hypothesis 3a: Greater beta power in resting EEG will be associated with 
poorer sensory gating performance and greater levels of nicotine dependence.  
 Hypothesis 3b: Variables presumed to underlie vulnerability to nicotine use, 
including family history of smoking, diagnosis, frequency spectral data, and 
sensory gating will significantly predict current use and level of nicotine 
dependence.   
The final aim of this study seeks to examine the extent to which variables thought to 
contribute to nicotine use are related to each other (hypothesis 3a), and to examine 
their individual and collective contributions (3b) to nicotine use. As the factors 
included in this working model are presumed to share common variance (e.g. genetic 
susceptibility to nicotine use may overlap with genetic susceptibility to schizophrenia; 
beta frequencies have been shown to contribute to sensory gating), the predictive 
power of all variables are considered together. The extent to which each variable 
contributes significant variance in predicting current nicotine dependence is of 
interest.  
While support for these hypotheses will not provide definitive evidence for a 
genetically mediated self-medication function for nicotine, support for, or refutation 
of, this hypothesis will help to lay the groundwork for future, more molecular studies 
investigating the pathophysiology of nicotine dependence in schizophrenia. In 
addition, while stimulus-evoked beta oscillations have been linked to sensory gating, 
this study will examine how resting beta oscillatory activity may be linked to 
information processing dysfunctions and nicotine use. Thus, in utilizing resting EEG 




findings from the addictions, schizophrenia, and electrophysiology literatures in an 
attempt to further explore the smoking phenomenon prevalent within the 
schizophrenia population.  
Additional Considerations 
 Current versus Past Smoking 
 The first two specific aims primarily consider any history of nicotine use, past 
or current. However, examining those factors which differentiate former and current 
smokers would be informative in elucidating the mechanisms responsible for 
susceptibility to addiction, or conversely, the factors associated with the ability to 
control substance use or to quit. Genetic influence is known to play a role in both 
smoking initiation as well as smoking persistence. Based on the trait-like natur  of 
oscillatory activity across the frequency spectrum in non-pathological and 
schizophrenia samples, it may be hypothesized that elevated beta band power also 
represents vulnerability to substance use, regardless of past or persistent use. 
However, inter-individual variability in beta power may also represent degree of 
cortical hyperexcitability, thereby reflecting degree of susceptibility to substance 
dependence. Thus, it might be hypothesized that those who initiate substance use but 
are more likely to quit are differentiated by level of cortical activation.  Limitations of 
statistical power must be taken into consideration in comparing former and current 






 Other Substance Use 
 Significant overlap between nicotine use and other substance use disorders are 
likely, given rates of both within schizophrenia samples and rates of comorbidity in 
the general population, as reported in prior research. This study attempts to control 
for the confounding effects of other substance in delineating the relationship between 
electrophysiological functions and nicotine dependence by limiting the clinical 
characteristics of the study sample with respect to current substance use. Individuals 
with some alcohol or drug use are not to be excluded all together, however, so as not 
to significantly bias the sample. Specific inclusion and exclusion criteria will be 
explicated in the following methodology section.  
 Psychotropic Medication 
 Individuals with schizophrenia must be maintained on their current 
medications during the assessment period. Psychotropic medications may include not 
only antipsychotic drugs, but concomitant medications, which may affect 
electrophysiological data. The pharmacological effects of certain psychiatri  drugs on 
EEG are documented to some extent in the general research literature. Evidence 
indicates that benzodiazepines increase activity in the beta band, while some evidence 
indicates that antipsychotic medications slow EEG activity, attenuating beta activity, 
although some findings indicate minimal to no influence of antipsychotic drugs on 
resting EEG (Itil, Saletu & Davis, 1972; Joutsiniemi, Gross, & Appelberg, 2001). 
Assessment of medication history of all research participants may warrant 





 Direct Effects of Smoking 
 Cigarette smoking is found to have direct effects on quantitative EEG 
(Domino & Matsuoka, 2003; Domino, Riskalla, Zhang & Kim, 1992; Newton, Cook, 
Holschneider, Rosenblatt, Lindhol & Jarvik, 1998). Studies of smokers from the 
general population have demonstrated changes in specific frequency bands such a
decreases in delta and theta power and increases in alpha and beta power (Kadoya,  
Domino, & Matsuoka, 1994). These effects appear to result from a shift of the overall 
power spectrum toward higher frequencies. Individual differences have, however, 
been noted irrespective of nicotine content of cigarettes smoked in laboratory 
paradigms and placebo effects of sham smoking on EEG activity have been 
documented (Domino & Matsuoka, 2003). These findings suggest the effects of 
additional factors in determining EEG activity other than the direct effects of 
nicotine. Additionally, nicotine induced changes in EEG activity have been reported 
under particular assessment conditions, namely following a brief period (e.g. 12 
hours) of smoking abstinence.  
The potential confound that cigarette smoking introduces in this study is 
considered to the fullest extent possible. First, in this study, participants maintain 
their normal smoking habits, except for a period of approximately 30 minutes prior to 
data collection during which laboratory preparations are completed. Thus, EEG 
power spectral data are not obtained under the influence of nicotine withdrawal or 
immediately after cigarette smoking. Similar constraints are placed on measurement 
of P50 gating.  Second, this study design provides the opportunity to examine 




Assessment of smoking history thus allows for examination of factors presumed to 
underlie nicotine use and addiction, rather than physiological changes as a result of 
immediate nicotine use. As the prolonged effects of nicotine exposure have not been 
clearly explicated in the literature, this study provides additional opportunities to 
clarify the nature of the relationship between nicotine use and specific components f 




Chapter 3: Methodology 
 In order to examine the specific aims, data were collected and analyzed in 
conjunction with a study titled “Familial Schizophrenia and Spectrum Personality 
Disorders”. Collection of study data was initiated in 2004 after receiving Institutional 
Review Board approval from the University of Maryland, Baltimore. This study has 
been ongoing and is being carried out by Dr. Gunvant Thaker, M.D., the Principal 
Investigator and chief of the Schizophrenia Related Disorders Program (SRD) at the 
Maryland Psychiatric Research Center (MPRC) in Catonsville, Maryland. Although 
data collection at the MPRC has been ongoing, it was the express and unique purpose 
of this protocol to examine the heritability of nicotine dependence in relation to a 
family history of schizophrenia, and to apply spectral power analysis methodology t  
nicotine use within the context of susceptibility to smoking in the schizophrenia 
population. Such analyses had not been utilized in this or other study samples at the 
MPRC. This study thus aimed to extend previous findings integrating assessments of 
beta oscillatory activity and sensory information processing by investigating the 
relationship between auditory P50 gating and beta power in EEG at rest, and 








 Study data were acquired from archived and continuous data collection at the 
Maryland Psychiatric Research Center. Recruitment of study participants ncluded (1) 
clinical case probands meeting Diagnostic and Statistic Manual – IV (DSM-IV) 
criteria for schizophrenia or Research Diagnostic Criteria (RDC) for schizoaffective 
disorder, (2) community comparison control probands matched with clinical case 
probands with respect to age, gender, and county of residence who did not meet 
DSM-IV criteria for schizophrenia or other psychotic disorders, (3) first-degree 
relatives (e.g. biological parents and siblings) of clinical case probands identified by 
the case proband, and (4) first-degree relatives of control probands identified by the 
comparison individual. Guidelines for recruitment of all participants is described by 
the inclusion/exclusion criteria and recruitment procedures as detailed below. 
 Criteria for study inclusion dictated that all participants were at leas 18 years 
of age, representing all ethnicities, both males and females. Individuals with erious 
medical, neuro-opthamological, or neurological illness (e.g. seizure disorder, 
encephalopathy), mental retardation, current (past 6 months) drug or alcohol abuse or 
dependence were excluded. Comparison controls drawn from the community were 






 Families with a first-degree relative diagnosed with schizophrenia were 
recruited via newspaper advertisements in the Baltimore/Washington D.C. 
metropolitan area. Some clinical case probands were recruited from individuals 
participating in outpatient programs at the Maryland Psychiatric Research Center. 
Potentially interested individuals with schizophrenia signed an informed consent 
form, giving permission to screen their medical records for eligibility, collect 
demographic information, and contact first-degree family members named by the
individual. Upon provision of contact information for first-degree relatives, a letter
sent through the mail requested family member participation. Attempts were mad  to 
recruit all relatives with contact information provided by the case proband. 
Recruitment letters were followed by phone calls. Letters and phone scripts were 
approved by the University of Maryland Baltimore IRB.  
 Comparison control probands were recruited from the Baltimore/Washington 
D.C. community. A pool of potential subjects was provided by a search of public 
records (e.g. Motor Vehicle Administration records) for individuals who matched 
clinical case probands in age, race, and county of residence. Individuals who met 
these criteria were contact first by letter and then by phone. For those who agreed to 
participate, contact information for first-degree relatives of comparison control 
probands was requested and recruitment of family members of control probands was 
initiated by letter. Recruitment letters were followed up by phone. Recruitment letters 
and phone scripts for community controls and family members were approved by the 




 Clinical case and control proband data were collected and analyzed even if 
their relatives did not participate. Failure to recruit relatives was due to (1) refusal to 
participate in the full “Familial Schizophrenia and Spectrum Personality Disorders” 
study, (2) ineligibility based on inclusion or exclusion criteria (e.g. age), or (3) 
residing out of area. For these individuals, an alternative method of participation ws 
offered. Family members who did not participate in the full study were contacted by 
letter and then by phone to request information about past or present smoking 
behaviors. Recruitment and data collection procedures were approved by the 
University of Maryland Baltimore IRB. 
 Study Assessments 
 After informed consent was completed, schizophrenia probands completed a 
battery of clinical assessments. Clinical data were extracted from the Structured 
Clinical Interview for DSM-IV Axis I Disorders (SCID) and Research Diagnostic 
Criteria (RDC), family history interview based on Family History Research 
Diagnostic Criteria (FH-RDC), and the Nicotine Dependence History including the 
Fagerstrom Test for Nicotine Dependence (FTND). Only schizophrenia probands 
who completed the nicotine dependence and EEG assessments were included in data 
analyses. For the schizophrenia probands, data from electrophysiological testng 
included P50 gating data and raw data from a five minute resting EEG sample. 
Unprocessed resting EEG data were subjected to data reduction and analyses for the 
appropriate outcome measures, which will be described below.  
 Data were obtained from the following assessments conducted with 




community control probands: sociodemographic information, medical history, family 
history interview based on FH-RDC (if not previously completed by a clinical case or 
community comparison proband), Nicotine Dependence History including the FTND, 
the SCID Non-Patient Version (SCID-NP), and the Structured Interview for DSM-IV 
Personality Diagnoses (SIDP). Only community control probands who completed the 
nicotine dependence and resting EEG assessments were included in analyses for this 
protocol. The SIDP was used only as a screening measure for personality diagnoses in 
the community participants; in the case of a positive diagnosis of a personality 
disorder, study data were not obtained. For family members, analyses were compl ted 
without regard for Axis II psychopathology. For community control probands, 
sociodemographic information, SCID-NP diagnosis (e.g. substance use disorder), 
nicotine dependence data, and data from electrophysiological testing including P50 
gating and a five minute resting EEG sample were obtained.  Electrophysiological 
data were obtained in an unprocessed form with the data from the patient probands 
without regard for diagnostic status. Thus, data reduction and analyses for the 
appropriate outcome measures were performed blind to group status.   
 Diagnostic Assessments 
 Structured Clinical Interview for DSM-IV (SCID; First, Spitzer, Gibbon & 
Williams, 1997): Masters and doctoral level trained clinicians from the MPRC 
Schizophrenia Related Disorders (SRD) Program routinely assess all study 
participants for Axis I disorders including mood disorders, psychotic disorders, 
alcohol and substance use disorders, and anxiety disorders using the SCID. Rater 




First, Spitzer & Davies et al., 1992). Diagnostic information on each patient was 
presented by the clinical interviewer in a best estimate diagnosis meeting at the 
MPRC, chaired by a senior psychiatrist. The SCID was used to verify a diagnosis of 
schizophrenia for the clinical case proband; diagnoses of alcohol and substance use 
disorders (not including tobacco dependence), disorders among control and patient 
probands were documented.  
 Family History Research Diagnostic Criteria (FH-RDC; Andreasen, Rice, 
Endicott, Reich & Coryell, 1986): SRD clinicians used the FH-RDC to screen for a 
family history of psychosis. To increase the sensitivity for Axis I diagnoses, 
especially schizophrenia, extensive probe questions were added to obtain additional 
information regarding each of the assessment items (e.g. hallucinations, delusions). 
Data were extracted as a dichotomous variable, family history positive or family
history negative. For those who are family history positive, the number of affected 
individuals within the family was ascertained by chart review. 
 Smoking and Nicotine Dependence Assessments 
 Nicotine Dependence Data including the Fagerstrom Test for Nicotine 
Dependence (FTND; Heatherton, Kozlowski, Frecker & Fagerstrom, 1991):  
Assessment of smoking and nicotine dependence was identical regardless of whether
individuals participated in the full study or only completed the nicotine dependence 
assessment over the phone. This data was acquired for schizophrenia and control 
probands as well as family members for whom data was available in study databases 
and family study chart records. All participants were first asked if they have ever 




participant currently smokes was ascertained (yes/no). If the participant smoked in the 
past but was not currently a smoker, the number of years since the individual quit 
smoking was calculated. The participant was asked to complete the FTND with 
respect to their current smoking behaviors, or if not applicable, then with respect to 
past smoking behaviors. Additional data included age at smoking initiation, age at 
which habitual smoking began, smoking years, number of quit attempts, and 
symptoms of nicotine withdrawal experienced during past quit attempts (see 
Appendix B for the full nicotine dependence assessment).  
 The FTND is a widely used measure of behaviors related to physiological 
nicotine dependence. The questionnaire consists of 6 self report items pertaining to 
amount of time to first cigarette of the day, difficulty refraining from soking, 
increased smoking in the morning, and the most difficult cigarette of the day to give 
up. The FTND yields a global score ranging from 0 to 10. A FTND score of 6 or 
higher identifies subjects with high nicotine dependence (Fagerstrom, Kunze, 
Schoberberger, Breslau & Hughes et al., 1996). The FTND has adequate internal 
consistency (coefficient α = 0.61; Heatherton et al., 1991) and has been shown to 
correlate with cigarette pack years, number of smoking related physical symptoms, 
exhaled carbon monoxide level, and cotinine level (Burling & Burling, 2003).  
Measures drawn from this assessment included dichotomous variables, “ever-
smoker” (yes/no) and “current-smoker” (yes/no); between-group variables also 
included classification as “current”, “former”, or “never-smoker”. Rates of moking 
were compared between proband groups and rates of ever and current smoking 




continuous variable, FTND total score, was also used in analyses. Additional data 
(e.g. smoking years) was available for some participants and was obtained for 
descriptive purposes in characterizing the smoking histories of the study sample. In 
supplementary analyses, smokers were classified dichotomously as nicotine 
dependent or not dependent based on a FTND total score equal to or greater than 4. 
This index has been used in prior investigations  (e.g.  Gelernter, Panhuysen, Wiess, 
Brady, & Poling, et al., 2007) to characterize nicotine dependence.  
Heritability Analyses: Smoking histories and nicotine dependence data 
collected from probands and their family members (derived from the FTND) were 
utilized to calculate heritability estimates for smoking. Pedigree and phenotyp  data 
were organized for each family unit utilizing available data from each proband and 
their participating parents and/or siblings with regard to history of ever smoking and 
current smoking. The SOLAR (Sequential Oligogenic Linkage Analysis Routines) 
software package (Almasy & Blangero, 1998) was used to calculate heritability 
estimates (h2) for patient and control pedigrees separately. This program allows for 
smoking data to be analyzed for relatives with varying kinship relations for pedigre s 
of varying size. A polygenic model was assumed; this analysis yields an estimated 
percentage of variance explained by genetic and environmental factors based on rates 
of smoking within families and the degree of genetic relationship between family
members. The heritability estimate represents the proportion of variance attributed to 
additive genetic effects; statistical significance of h2 was determined by computing 
the log likelihood between the polygenic model and a sporadic model with a 




The significance of each heritability estimate and covariates will be reported for each 
model tested.  
 Electrophysiological Assessments 
 Set Up: The procedures for electroencephalogram (EEG) measures consisted 
of the application of electrodes to the scalp and face, the performance of a number of 
simple tasks while EEG data was acquired, removal of electrodes, and clean up. 
Recordings were obtained from a cap with up to Ag/AgCl active electrodes 
referenced  to linked ears. Vertical and horizontal oculograms were recorded as w ll. 
Skin impedance was maintained at less than 10 kOhms. EEG data were collected 
using a Neuroscan SynAmp amplifier running under Acquire software. EEG data for 
a battery of tasks were collected in succession, typically within one testing session. 
Data acquisition uniformly began with resting EEG.  
Resting EEG: The subject was seated in a comfortable chair in an enclosed, 
sound-attenuated room under controlled lighting conditions. Participants were 
instructed to keep their eyes closed but not to fall asleep for five minutes while data 
were acquired. Resting recordings were acquired as continuous EEG data; raw data 
for analyses were obtained in an unprocessed form and then subjected to filtering, 
artifact rejection, and time/frequency analysis offline. Data processing was completed 
using the Neuroscan software.  
Data reduction and analyses were based on procedures and parameters 
described by Rangaswamy and colleagues (2002; 2004) and guidelines for EEG 
analyses described by Pivik and colleagues (Pivik, Broughton, Coppola, Davidson, 




parietal, and occipital scalp locations. However, prior studies have found the most 
consistent significant increases in power across the beta frequency spectrum at he Fz-
Cz lead pair, differentiating alcohol dependent individuals from healthy controls. 
Thus data from two electrodes, Fz and Cz, were utilized for statistical analyses in 
schizophrenia and healthy control samples in this study. In order to preliminarily 
assess the consistency of data recordings across the 5 minute sample, markers 
(marker type 1 and marker type 2) were inserted alternately every 2 seconds through 
the duration of continuous raw data recording for each participant, yielding in total 
144 markers; data reduction and bandpower analyses, described below, were 
conducted on the basis of type 1 and type 2 EEG data. All statistical analyses of 
power for each defined frequency band were based on an average of type 1 and type 2 
data derived for each individual, thereby providing the full duration of EEG recording 
for analyses.   
Data reduction methods performed with Neuroscan software were as follows. 
Continuous data was analyzed in 2 second epochs. Baseline correction was performed 
across the entire sweep utilizing data from all channels. Artifact rejection was based 
on criteria of -100µV and 100µV at the ocular, Cz, and Fz electrode sites. Data were 
aggregated into bands and averaged across epochs. Bandpass filters were applied to 
calculate absolute power in the alpha (8-12 Hz), beta (12.0 – 28.0 Hz), and gamma 
(30 – 50 Hz) frequency bands. Parameters for the bandpower analysis varied slightly 
between frequency spectra due to edge effects that varied with frequency. For power 
in the alpha band, each 2 second epoch was trimmed at the beginning and end by 




gamma frequency bands, epochs were trimmed at either end by 100ms, yielding 
1800ms epochs that were averaged together in the bandpower analysis. Data were 
visually inspected for errors in recording or processing and for significant noise
which excluded bandpower data from 7 subjects. Bandpower across the frequency 
spectrum was converted from Neuroscan to data files in Excel; mean bandpower for 
electrode sites Cz and Fz were calculated across time for each epoch.  Mean 
bandpower was log transformed to normalize the sample distributions (Pivik et al., 
1993) and subjected to statistical analysis in accordance with the second specificaim 
of the study.  
The second study aim was to examine the relationship of EEG activity in the 
beta band to nicotine use history, and to compare whether this relationship varies with 
respect to a diagnosis of schizophrenia. Repeated Measures Analysis of Variance was 
used to examine this specific aim for power in the alpha, beta, and gamma frequency 
bands. Gender and past substance use were considered as variables in preliminary 
analyses in addition to diagnostic group and smoking status in main analyses. Main 
effects and interactions for between-group variables were examined. 
P50 Auditory Evoked Potentials: Participants are instructed to keep their eyes 
open and listen to paired click stimuli through headphones. Auditory stimuli were 
generated by a programmable sound module (Neuroscan) and delivered at a sound 
intensity of 75dB. Auditory clicks were delivered in pairs with a 500ms inter-click 
interval, at a rate of 1 pair every 10 seconds for a total of 150 pairs.  Auditory evoked 
potentials were obtained and averaged from the paired click stimuli. S1 denotes the 




latency measurements were gathered from averages obtained from electrod  position 
CZ. For the S1 response, P50 was defined as the largest positive wave occurring 
within a 35 to 70ms interval following the stimulus. Amplitude was measured from 
the trough of the preceding wave to the P50 peak. Measurement of the response to the 
second click (S2) was limited to a latency window 10ms before or after the S1 P50 
latency. Gating of the P50 response was quantified by the ratio of the amplitude of the 
second response to the first response. In the P50 gating paradigm, a decremented 
evoked response to the second auditory stimulus is expected, as inhibitory 
mechanisms activated by the first auditory stimulus attenuate the secondary reaction 
(Adler et al., 1982). A failure to suppress the second response indicates that the 
inhibitory mechanism is impaired (Adler et al., 1999). Disrupted gating was define  
as a S2/S1 ratio that exceeds 0.50 (Freedman, Adler, Myles-Worsely, Nagamoto & 
Miller et al., 1996).  Data were extracted as S1 and S2 amplitudes and the S2/S1 ratio. 
For exploratory purposes, continuous P50 data were also classified dichotomously as 
being “impaired” or “unimpaired.” 
 Sensory gating performance was compared between patients with 
schizophrenia and controls and interactions with smoking status were considered as 
well. The relationships between P50 gating performance and level of nicotine 
dependence, and P50 gating performance and resting EEG power across the 
frequency spectrum were examined. In accordance with the third specific aim, the 
contribution of electrophysiological data (P50 ratio and bandpower) to history of ever 




Chapter 4: Results 
 This study utilized four groups to examine three multi-level study aims. In this 
section, participants from each group will first be described with respect to 
demographic characteristics as well as past and present alcohol and drug use. The 
three specific aims and the hypotheses contained within each will then be described, 
and statistical analyses and results will be reported.  
Participants 
 Participants included (1) 141 probands affected by schizophrenia or 
schizoaffective disorder recruited from outpatient programs at the Maryland 
Psychiatric Research Center, (2) 158 first-degree relatives of affected probands, (3) 
109 healthy comparison control probands recruited from the Baltimore/Washington 
D.C. area, and (4) 44 first-degree relatives of comparison control probands. Based on 
availability of data provided by index probands, recruitment efforts targeted 78 
patient families (55.32% of patient probands) and 35 control families (32.11% of 
control probands). Of those probands who identified first-degree relatives, there was 
no statistically significant difference in actual recruitment rates b tween patient and 
control groups (χ2 = 0.75, p = 0.39). For each proband who had a family member 
recruited, between 1 and 6 first-degree relatives participated. For patients w th 
schizophrenia, successful recruitment resulted in a family group composed of equal 
numbers of siblings and parents, whereas first-degree relatives of comparison controls 




Patient and control probands were compared on demographic characteristics 
including sex, age, and race/ethnicity. The distributions for proband demographic 
characteristics are represented in Figure 1. In both groups, participants were 
predominantly Caucasian (54 patients and 53 controls) and Black/African American 
(45 patients and 21 controls). There were no statistically significant differenc s with 
respect to the proportion of males and females in each proband group (χ2 = 0.49, p = 
0.48), with respect to the rates of participant-identified race or ethnicity (χ2 = 4.66, p 
= 0.46), nor with respect to mean age (F(1,249) = 0.006, p = 0.94). 
Figure 1. Demographic Characteristics  








































Pat ient  Probands
Contro l Probands
 
 Community participants were excluded from the study if a family history of 
schizophrenia-spectrum disorder was present. Within the patient proband group, 
14.4% reported having at least one first-degree family member with schizophrenia (n 
= 7) or schizophrenia spectrum personality disorder (schizotypal or schizoid 
personality disorder; n = 8). Patient and control participants were screened for 
lifetime and current substance abuse or dependence. Among probands and family 
members screened (N = 360), 11.8% reported a history of lifetime alcohol abuse and 
9.5% reported a history of lifetime alcohol dependence. Among all participants 




stimulant, opioid, cocaine, hallucinogen, poly-substance, or other drug use) and 
14.8% reported a history of lifetime drug dependence. In the patient proband group 
alone, 38.5% reported any lifetime alcohol/drug abuse or dependence with 2.7% 
reporting current diagnostically significant substance use. In the control group, 24.4% 
reported any lifetime alcohol/drug abuse or dependence with 1.2% reporting current 
substance use.  
Specific Aim 1: Smoking and Nicotine Dependence 
 Specific aim 1 sought to compare rates of smoking and the heritability of 
smoking among individuals with and without a family history of schizophrenia in 
order to characterize rates of nicotine use in the study sample, and examine the 
association between smoking and vulnerability for the illness. Based on prior resea ch 
demonstrating elevated rates of smoking and nicotine dependence among individuals 
with schizophrenia, hypothesis 1a proposed that the prevalence of nicotine use, past 
or present, would be greater among patient probands than healthy comparison 
controls. This hypothesis also proposed that the prevalence of smoking would be 
greater among first-degree relatives of affected probands than first-degree relatives of 
probands drawn from the general population.  
 Smoking Prevalence 
Nicotine dependence data was available for 141 probands with 
schizophrenia/schizoaffective disorder and 109 comparison controls.  Rates of 
smoking were compared utilizing Pearson Chi-Square analyses; these results are 




different between patients and controls (χ2 = 12.49, p < 0.001) with 68.1% of patients 
and 45.9% of controls reporting ever smoking.  Among the patient group, 11.4% were 
former smokers, compared to 24.8% of controls; among those with any smoking 
history, a greater proportion of control probands (50%) than patient probands (15.3%) 
were former smokers (χ2 = 14.73, p <0.001). The difference between proband groups 
for the rate of current smoking was also statistically significant (χ2 = 31.05, p < 
0.001) with 56.0% of patients and 21.0% of controls reporting current smoking. To 
further characterize differences in smoking history across diagnostic groups, years of 
smoking was compared; patient and control probands reported a mean number of 
smoking years of 20.4 (SD = 12.3) and 15.6 (SD = 12.8) respectively. An 
independent samples t-test indicated that this difference was not statistically 
significant (p = 0.06). 
 Ever smoking and current smoking were also examined using Chi-Square 
analyses in the subgroup of patient probands with a family history of schizophrenia-
spectrum disorder. Among patient probands who were family history positive (n = 
15), 12 reported a history of ever smoking and 3 reported no smoking history (χ2 = 
2.73, p = 0.09). Ten patient probands reported current smoking and 5 were classified 
as former or never smokers; Chi-Square values for current smoking relative to family 








Figure 2. Smoking Status 
Proband Smoking Status




















Patient Probands (N = 141)
Control Probands (N = 109)
 
 Nicotine Dependence 
Mean levels of self-reported nicotine dependence were compared between 
patient and control proband groups utilizing ANOVA for total score on the 
Fagerstrom Test for Nicotine Dependence (FTND). Among patients (N = 94) and 
controls (N = 46) who reported a history of ever smoking, patient probands reported a 
mean total score of 4.55 (SD = 2.24), which was significantly greater than the mean 
total score of 2.96 (SD = 2.23) for the control probands (F(1, 140) = 15.632, p < 0.001). 
On the basis of a total FTND score of 4 or greater, participants were also categ rized 
dichotomously as nicotine dependent or not dependent and rates of nicotine 
dependence were compared between groups using a Chi-Square analysis. Results are 
presented in Figure 3. Among ever smokers, patients were more likely to be 
categorized as nicotine dependent (63.57%) than controls (43.48%; χ2 = 11.94, p = 
0.001). Among patients (N =79) and controls (N = 23) who reported current smoking, 
patient probands reported a mean total FTND score of 4.58 (SD = 2.24), which was 
significantly greater than the mean total score of 3.22 (SD = 2.11) for the control 








FTND scores between patient and control probands was also quantified by calculating 
Cohen’s d. Effect sizes for level of nicotine dependence were in the medium range for 
ever smokers (d = 0.71) and current smokers (d = 0.63). 
Figure 3. Nicotine Dependence 
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*** ** *** *
 ** p = 0.01  
*** p < 0.001
   * p < 0.05 
*** p = 0.001
 
Compared dichotomously, rates of nicotine dependence were greater (χ2 = 4.74, p = 
0.029) among current smokers with schizophrenia/schizoaffective disorder (66.67%) 
than among comparison current smokers from the general population (47.83%). 
These results are also summarized in Figure 3.  
 Familial Patterns of Nicotine Use 
 A second goal within specific aim 1 was to examine patterns of nicotine use in 
families with or without a history of schizophrenia/schizoaffective disorder. The 
smoking habits among participating first-degree relatives were preliminarily 
characterized, followed by a more rigorous analysis of nicotine use patterns, for 
which heritability estimates for smoking were calculated separately for those families 
affected and unaffected by schizophrenia/schizoaffective disorder. Among all 




158 (40.51%) reported a history of ever smoking and 21 out of 158 (13.29%) reported 
currently smoking. Among all participating first-degree relatives of controls 
probands, 17 out of 44 (38.64%) reported a history of ever smoking and 8 out of 44 
(18.18%) reported currently smoking. These differences were not statistically 
significant (χ2 = 2.81, p = 0.25 and χ2 = 2.70, p = 0.26 for rates of ever and current 
smoking, respectively).  
 The heritability analysis for nicotine dependence was conducted to test 
hypothesis 1b, that genetic contributions to nicotine use would be greater among 
those family history positive for schizophrenia, compared to healthy comparison 
subjects and their relatives. The heritability analysis differs from the preliminary 
characterization of nicotine use patterns by taking into account the smoking status of 
the schizophrenia or control proband and the degree of genetic relationship among 
participating family members (i.e. parent or sibling status). A polygenic model was 
assumed in estimating the heritability (h2) for ever smoking and current smoking. For 
each analysis, age and sex were entered into the model as covariates.  
Table 1 presents information on family unit size for patient and control groups 
utilized in the heritability analyses.  Importantly, 112 sibling-sibling pairs and 110 
parent-offspring pairs were included in the heritability analyses for the pati nt group 
while 23 sibling-sibling pairs and 25 parent-offspring pairs within the control group 
were available for analyses.  
In the patient group, the heritability estimate for history of ever smoking was 
h2 = 0.9236 (SE = 0.20), which was significant at p = 0.00001. Both age (p = 0.02) 




group, h2 = 0.9674 (SE = 0.31) which was statistically significant at p = 0.0008. Both 
age (p = 0.049) and sex (p = 0.00001) were significant as covariates. 
Table 1. Family Unit Descriptives: Heritability Analyses for Smoking History 
 
Family Unit Size 
Number of Patient 
Family Units 
Number of Control 
Family Units 
Family Unit n = 2 48 29 
Family Unit n = 3 21 5 
Family Unit n = 4 8 1 
Family Unit n = 5 5 0 
Family Unit n = 6 1 0 
Family Unit n = 7 1 0 
 
In the control group, the heritability estimate for history of ever smoking was 
h2 = 0.9306 (SE = 3.86) which was significant at p = 0.024. Both age and sex were 
significant as covariates (p = 0.0004 and p = 0.039 respectively). For current smoking 
in the control group, h2 = 0.515 (SE = 0.63) which was not statistically significant (p 
= 0.23). Covariates were entered but not included in the final model, as age (p = 0.44) 
and sex (p = 0.87) were not statistically significant.  
 Summary of Main Findings: Specific Aim 1 
 The prevalence of ever and current smoking was significantly elevated among 
patients with schizophrenia/schizoaffective disorder relative to demographically and 
geographically matched healthy comparison controls drawn from the general 
population. Among index probands who reported a positive smoking history, mean 
number of smoking years was not significantly  different between groups but patients 
self-reported a greater level of nicotine dependence and were less likely to have quit 




were highly significant and appear comparable among those with and without a 
family history of schizophrenia.   
Specific Aim 2: Smoking and Bandpower in Resting EEG 
 Specific aim 2 sought to examine the hypothesis that abnormalities in the 
power of resting EEG, particularly in the beta frequency band, would be associated 
with nicotine use, as given by prior reports of the association of elevated beta 
bandpower with alcohol and other substance use disorders. Preliminary analyses 
sought to characterize the sample of patient (N = 104) and control (N = 78) probands 
whose EEG and smoking history data were both available for analyses. This subset of 
participants excluded 1 patient and 1 control, both with current alcohol dependence, 
and excluded 7 participants with faulty EEG recordings (i.e. data unscorable due to 
irremovable artifact or errors in recording). No significant differences between 
patients and controls were found for any demographic characteristics in this 
subgroup, including mean age (F(1, 178) = 0.46, p = 0.50), the proportion of males and 
females (χ2 = 1.06, p = 0.30), and the proportions of individuals identifying with 
racial or ethnic groups (χ2 = 6.109, p = 0.19). Preliminary analyses also sought to 
characterize and compare groups on the basis of smoking history. Patient probands 
within this subset of participants were more likely than control probands to report 
ever smoking (69.9% versus 46.75%; χ2 = 9.84, p = 0.002) and current smoking 
(58.25% versus 23.38%; χ2 = 21.83, p < 0.001). Patient probands also reported 
greater mean nicotine dependence on the FTND (F(1,76) = 9.64, p = 0.003). When 




4, a greater number of patients (75.0%) than controls (44.4%) were characterized as 
nicotine dependent (χ2 = 5.936, p = 0.015). 
 Prior to hypothesis testing for resting EEG bandpower, mean power values 
were log transformed and the reliability of EEG power was examined for alpha, beta, 
and gamma frequency band activity for patient and comparison control probands 
separately. Intraclass correlation coefficients (ICCs) were calculated for type 1 and 
type 2 EEG data to test the consistency of data recordings over time (5 minutes). I  
the patient group, EEG data in the alpha, beta, and gamma bands were highly 
consistent with values of 0.968, 0.979, and 0.991 respectively at electrode site Cz and 
values of 0.960, 0.963, and 0.988 for alpha, beta, and gamma frequency bands at 
electrode site Fz. Similarly, data from the control proband group showed high ICCs 
with values of 0.970, 0.990, and 0.984 for alpha, beta, and gamma bandpower 
respectively at electrode site Cz and values of 0.963, 0.988, and 0.986 for alpha, beta, 
and gamma frequency bands at electrode site Fz.  
In the total sample (N = 180), preliminary analyses revealed no significant 
main effect for sex or race/ethnicity, and no significant correlations with age for mean 
alpha and mean beta bandpowers (all p values greater than 0.10), or gamma 
bandpower (all p values greater than 0.05). Demographic variables were therefore not 
included as covariates in subsequent analyses. Mean log transformed bandpower was 
also preliminarily examined by gender. ANOVA revealed no statistically significant 
differences in power between males and females at either electrode site with p values 




differences in bandpower in this study sample, subsequent between-groups analyses 
were also performed without entering gender as a covariate.  
In accordance with specific aim 2, three hypotheses were proposed to examine 
the relationship between smoking and resting EEG. First, it was hypothesized that 
beta power in resting EEG would be elevated in those with a smoking history relative 
to those with no history of nicotine use. Second, it was hypothesized that differences 
in beta bandpower would also be affected by diagnostic status whereby probands with 
schizophrenia would demonstrate elevated power relative to control probands. Third, 
it was hypothesized that a significant relationship between resting EEG power and 
smoking history would be specific to beta activity as compared to power in the alpha 
and gamma frequencies.  
The group means for averaged log transformed bandpower values for 
electrode sites Cz and Fz are presented in Table 2.  







(N = 103) 
M (SD) 
Control Probands 




Cz 1.51 (0.46) 1.49 (0.64) 
Fz 1.49 (0.44) 1.43 (0.59) 
Beta 
(12-28 Hz) 
Cz 1.55 (0.38) 1.54 (0.49) 
Fz 1.55 (0.35) 1.51 (0.46) 
Gamma 
(30-50 Hz) 
Cz 0.97 (0.32) 0.94 (0.39) 





Hypotheses associated with specific aim 2 were addressed with repeated 
measures ANOVA using electrode site (Cz and Fz) as within-subjects factors, and 
between-subjects factors including group (patient and control) and smoking status 
(never, former, current smoker). Mean log transformed power data by diagnostic and 
smoking group are presented here in Table 3. Within-subjects results demonstrated a 
significant effect for electrode site for alpha bandpower only (F(1, 174) = 4.66, p = 
0.03), but there were no significant interactions between electrode site and group (F(1, 
174) = 0.23, p = 0.64) or smoking status (F(2, 174) = 0.95, p = 0.39).  
Table 3. Mean Log Transformed Bandpower and Smoking Status 
 































Cz 1.44 (0.41) 1.63 (0.24) 1.52 (0.51) 1.50 (0.51) 1.64 (0.36) 1.33 (1.00) 
Fz 1.35 (0.53) 1.60 (0.26) 1.54 (0.40) 1.43 (0.49) 1.59 (0.31) 1.27 (0.93) 
Beta 
(12-28 Hz) 
Cz 1.54 (0.33) 1.69 (0.17) 1.53 (0.43) 1.56 (0.39) 1.63 (0.23) 1.37 (0.80) 
Fz 1.51 (0.36) 1.73 (0.18) 1.55 (0.36) 1.54 (0.37) 1.02 (0.24) 1.35 (0.73) 
Gamma 
(30-50 Hz) 
Cz 0.97 (0.31) 1.10 (0.29) 0.95 (0.33) 0.96 (0.24) 1.02 (0.24) 0.81 (0.68) 
Fz 0.95 (0.33) 1.13 (0.29) 0.92 (0.35) 0.97 (0.25) 1.02 (0.62) 0.79 (0.62) 
 
Repeated measures ANOVA revealed no significant main effect for smoking 
status for log transformed power in the alpha (F(2, 174) = 1.66, p = 0.19) or beta (F(2, 174) 
= 2.62, p = 0.07) frequency bands. There was a significant main effect for smoking 
status in the gamma frequency band (F(2, 174) = 3.34, p = 0.03). Post-hoc comparisons 




this main effect of smoking status was due to a significant difference in bandpower 
between former and current smokers (p = 0.03) such that current smokers 
demonstrated lower mean bandpower in the gamma band than former smokers2. 
Given that this pattern of lower power among current smokers, relative to 
former smokers, was observed in the alpha and beta frequency bands as well, effect 
sizes were calculated to assess the magnitude of the differences between curr nt and 
former smokers across the frequency spectrum; effect sizes were in the small range 
for differences in the alpha frequency band and in the medium range for differences 
in the beta and gamma frequency bands. These results are summarized in Table 4. 
Table 4. Bandpower Differences Between Current and Former Smokers 
 
  Schizophrenia 
Probands (N = 103) 
Control 





Cohen’s d Cohen’s d 
Alpha 
(8-12 Hz) 
Cz 0.28 0.41 
Fz 0.18 0.46 
Beta 
(12-28 Hz) 
Cz 0.49 0.44 
Fz 0.63 0.61 
Gamma 
(30-50 Hz) 
Cz 0.48 0.41 
Fz 0.65 0.37 
 
Hypotheses 2a and 2c were not supported in that beta bandpower did not significantly 
vary relative to smoking status. Rather evidence for an association between gamma
bandpower and smoking status was demonstrated. Repeated measures ANOVA 
revealed no significant main effect of group on log transformed power in the alpha 
(F(1, 174) = 0.34, p = 0.56), beta (F(1, 174) = 1.43, p = 0.23), or gamma (F(1, 174) = 1.59, p 
                                                
2 As there was no within-subjects effect for electrode site for beta and gamma frequency bands, values 
for Cz and Fz were averaged for each and univariate ANOVAs were conducted using collapsed log 
transformed bandpower. Patterns of results were unchanged for between-subjects effects of diagnostic 
group and smoking status for both frequency bands, and post-hoc differences between former and 




= 0.21) frequency bands. Group by smoking status interactions were not significant 
for log transformed power in the alpha (F(2, 174) = 1.33, p = 0.26), beta (F(2, 174) = 1.07, 
p = 0.35), or gamma (F(2, 174) = 0.02, p = 0.54) frequency bands. These results 
therefore do not support hypothesis 2b. These and other results from post-hoc 
analyses (described below) examining relationships between smoking status, 
diagnosis, and resting EEG are summarized in Table 5. 
Table 5. Repeated Measures ANOVA Bandpower Comparisons 
 























F = 0.34 
p = 0.56 
F = 1.66 
p = 0.19 
F = 1.33 
 p = 0.26 
F = 2.24 
p = 0.14 
F = 1.25  
p = 0.26 
F = 1.11  
P = 0.29 
Beta 
(12-28 Hz) 
F = 1.43 
p = 0.23 
F = 2.6 
p = 0.07 
F = 1.07 
 p = 0.35 
F = 2.27 
p = 0.13 
F = 2.08 
p = 0.15 
F = 1.63 
P = 0.20 
Gamma 
(30-50 Hz) 
F = 1.59 
p = 0.21 
F = 3.34 
p = 0.03 
F = 0.02 
 p = 0.54 
F =2.84  
p = 0.09 
F = 5.07  
p = 0.02 
F = 0.12 
p =  0.52 
 
Specific Aim 2: Post-Hoc Analyses 
 Effects of Nicotine Dependence on Bandpower 
Considering that the group classified as “never smokers” is likely to be 
heterogeneous in that factors contributing to their current non-smoking status are 
unknown (i.e. due to a lack of exposure to smoking in psychosocial environment, 
occasional cigarette use without the development of a regular pattern of smoking, 
etc), repeated measures ANOVA was conducted to examine the relationship between 




current smokers. Current smokers represent a group who have had exposure to 
cigarette use and currently demonstrate a regular smoking pattern. These individuals 
reported currently smoking at least 1 cigarette per day and included 60 patient and 18 
control probands. Current smokers were classified dichotomously on nicotine 
dependence, based on a FTND Total Score of greater than or equal to 4; of all current 
smokers in the sample, 25 were classified as non-dependent and 53 current smokers 
were classified as dependent. 
Between-subjects factors included both patient or control status and nicotine 
dependence status. Repeated measures ANOVA again revealed no statistically 
significant main effects for group across the frequency spectrum, and no statistically 
significant main effects for nicotine dependency for power in the alpha (p = 0.26) or 
beta (p = 0.15) frequency bands. Classification by nicotine dependency yielded a 
significant main effect for gamma bandpower (F(1, 74) = 5.07, p = 0.02). Group by 
nicotine dependency status interactions were non-significant across frequency bands 
(all p values 0.20 or above). 
Given the significant effect of smoking status on power in the gamma 
frequency band and the same significant effect of nicotine dependency among curre t 
smokers, zero order correlations were calculated to examine the strength of the 
relationship between variations in power and level of nicotine dependence. Despite 
the statistical significance of differences in gamma power when current smokers were 
dichotomized according to a cut-off score on the FTND, correlation analyses 
including log transformed power in the alpha, beta, and gamma frequency bands and 




 Effects of Medication on Bandpower 
As certain psychotropic drugs are known to affect EEG in predictable 
patterns, and individuals with schizophrenia are likely to be treated with such 
medications, post-hoc analyses were conducted, excluding individuals based on a 
review of medication records. In the patient sample, 12.8% of individuals were 
currently prescribed clozapine; clozapine has been shown to shift bandpower towards 
slower frequencies. Thus, to determine whether differences in power were 
significantly influenced by antipsychotic medication status, repeated measures 
ANOVA was conducted excluding 23 patients prescribed clozapine, using electrode 
site as the within-subjects factor and group (patient or control) and smoking status 
(never, former, current) as between-subjects factors.  
Table 6. Post-Hoc Bandpower Comparisons 
 






















F = 0.02 
p = 0.89 
F = 1.47 
p = 0.23 
F = 0.94 
p = 0.39 
F = 0.04 
p = 0.83 
F = 1.49 
p = 0.23 
F = 0.92  
P = 0.40 
Beta 
(12-28 Hz) 
F = 0.34 
p = 0.56 
F = 2.82 
p = 0.06 
F = 0.80 
p = 0.45 
F = 0.72 
p = 0.39 
F = 2.47  
p = 0.08 
F = 0.92 
P = 0.40 
Gamma 
(30-50 Hz) 
F = 0.95 
p = 0.33 
F = 3.59 
p = 0.03 
F = 0.62 
p = 0.54 
F = 1.16 
p = 0.28 
F = 3.14  
p = 0.04 
F = 0.69 
p =  0.49 
 
Within-subjects results revealed no significant effects of electrode site in any 
frequency band (main effect for electrode site was no longer significant for alpha 
bandpower, F(1, 151) = 2.92, p = 0.09).  Results for between-subjects comparisons are 




power in the alpha or beta frequency bands but the main effect of smoking status on 
power in the gamma frequency band remained significant (p = 0.03). Main effects for 
group were not significant across the frequency spectrum. Similarly, group by 
smoking status interactions were not significant for any bandpower spectrum. Th s 
the original pattern of results reported was not significantly affected by inclusion or 
exclusion of individuals prescribed the antipsychotic drug clozapine. 
Anxiolytic medications belonging to the benzodiazepine class of drugs are 
also commonly prescribed among individuals with mental illness and have been 
shown to affect resting EEG by increasing beta band activity. In this sample, 6.7% 
were currently prescribed a benzodiazepine (e.g. alprazolam, clozazepam, 
lorazepam); the general linear model was retested with repeated measures ANOVA, 
excluding 11 patients and 1 control proband, to ensure that the primary findings were 
not significantly affected by the effects of this class of medication. Within-subjects 
results indicated a significant effect of electrode site for alpha bandpower only (F(1, 
162) = 4.45, p = 0.03). Main effects for smoking status were not significant for power 
in the alpha or beta frequency bands. Similar to the results reported from the full 
group, the main effect of smoking status was significant for power in the gamma 
frequency band (F(1, 162) = 3.14, p = 0.04). The main effect of diagnostic group was 
not statistically significant across the frequency spectrum and there was no significant 
interaction between group and smoking status. 
 Summary of Main Findings: Specific Aim 2 
 Data reduction of a five minute resting EEG sample yielded means for log 




smokers demonstrated relatively increased power across the frequency band range 
from alpha to gamma. Repeated Measures ANOVA revealed a main effect for 
smoking status in the gamma frequency range with significant differences in mean 
log transformed bandpower between current and former smokers. Statistical analyses 
did not yield support for the proposed hypotheses as no specific abnormalities in the 
beta frequency band were found with respect to smoking status or diagnostic group.  
 Relative increases in bandpower among former smokers may suggest long-
term effects of nicotine on resting EEG. Alternatively, lower bandpower in current 
smokers may be reflective of an underlying state of low activity which is 
subsequently elevated by nicotine, or may, to some extent, reflect a state of nicotine 
withdrawal. Causality could not be determined by these data.  Notably, in secondary 
analyses, a significant effect of nicotine dependency based on total FTND score was 
observed for gamma power in a subgroup of current smokers whereby those who 
were classified as being dependent exhibited lower power than non-dependent 
smokers. Correlational analyses, in contrast, did not yield significant associ tions 
between level of nicotine dependence (i.e. continuous FTND total score) and power 
across the alpha through gamma frequency bands. 
Specific Aim 3: Relationships Among Putative Susceptibility Factors 
 P50 Gating 
The final specific aim sought to investigate the relationships among variables 
hypothesized to be associated with nicotine use. Hypothesis 3a predicted a 
relationship between sensory gating performance on the P50 gating paradigm an  




dependence. It was predicted that poorer sensory gating, indicating deficient neural 
inhibition, would be associated with elevated beta power, as an indicator of an 
imbalance between cortical inhibition and excitation. Based on prior hypotheses that 
nicotine use represents an effort to improve cognitive functioning, including sensory 
information processing, it was predicted that poorer sensory gating would be 
associated with greater nicotine dependence. Univariate ANOVA was conducted to 
test differences in P50 gating performance by diagnostic and smoking status, first on
the basis of ever versus never smoker, and then on the basis of current smoking 
status.  Means for P50 ratio (S2/S1) are reported for patients and controls in Table 7. 
The mean differences in P50 component amplitudes are shown as well as an alternate 
representation of P50 gating performance and descriptive purposes. 






































































Univariate ANOVA testing the effects of diagnostic and smoking status on 
P50 ratio revealed no significant main effect of diagnostic group (F(1,89) =  0.55, p = 
0.46) and a significant main effect of smoking status (F(2,89) = 3.88, p = 0.02). There 




status (F(2,89) = 4.65, p = 0.01) whereby nicotine use appeared to affect P50 gating in 
patients (i.e. normalizing deficient gating) but not in controls. Univariate ANOVA 
was repeated examining the effects of diagnostic group and smoking status, with the 
exclusion of former smokers, comparing current and never smokers only. Again, the 
main effect of diagnostic group on P50 was not significant (F(1,81) = 2.05, p = 0.15) 
but there was a significant main effect of current smoking (F(1, 81) = 7.87, p = 0.006) 
and a significant disordinal group by smoking status interaction  (F(1,81) = 9.11, p = 
0.003). This interaction is depicted in Figure 4.  
 










 In the full group of current smokers, P50 ratio was not significantly correlated 
with FTND Total Score (p = 0.29) and t-tests revealed that FTND Total Score did not 
significantly differ between current smokers with impaired (4.67 ± 2.22) and 
unimpaired (4.71 ± 2.10) P50 gating (p = 0.94). Given the significant interactions 
between diagnostic group and smoking status, the effect size for P50 was calculated 
for never smokers in order to directly compare P50 gating performance between 
P50 Gating
Smoking Status


















patients and controls without the confound of current or past nicotine use. This 
analysis yielded an effect in the medium range (Cohen’s d = 0.56) supporting prior 
evidence for impaired P50 gating in patients with schizophrenia relative to heal hy 
comparison controls. Subsequent analyses were conducted to further examine the 
relationships between current nicotine use and electrophysiological activity.   
 In both patient and control smokers, correlations between power in the alpha, 
beta, and gamma frequency bands and P50 ratio were not statistically significant (all 
p values greater than 0.10). However, distinct relationships between power and P50 
components were demonstrated among current smokers. Among patient probands (N 
= 65), power in the gamma frequency band was significantly correlated with S1 
amplitude at Cz (r = 0.35, p = 0.004) and Fz (r = 0.33, p = 0.007) electrode sites, and 
with S2 amplitude at Cz (r = 0.25, p = 0.04) and Fz (r = 0.25, p = 0.04) electrode 
sites. When current smokers in the patient group were considered independently, the 
relationship between S1 and gamma power remained significant at both Cz (r = 0.57, 
p < 0.001) and Fz (r = 0.51, p = 0.001) electrode sites but these effects were 
diminished when patient never smokers were considered alone (r = 0.29, p = 0.07 and 
r = 0.26, p = 0.10 for Cz and Fz sites respectively).  
 The pattern of relationships between bandpower and P50 components with 
gamma bandpower and P50 components differed in the control group (N = 20). The 
strength of association between gamma bandpower and P50 components was lower in 
the control group, with r values ranging between 0.19 and 0.25 (p values of 0.27 and 
above). However, there was a significant correlation between S1 amplitude and 




0.04) electrode sites. The number of control smokers was too small for these analyses 
to yield meaningful comparisons between smokers and never smokers. Overall, 
greater amplitude responses in the P50 gating paradigm were associated with greater 
power across the frequency spectrum, yet these relationships were statistically 
significant at the higher and lower ends of the frequency bands examined in patient 
and controls respectively. Within the patient group, significant relationships between 
gamma power and P50 components were limited to current smokers. Thus, although 
these findings are significant, hypothesis 3a was not supported in that P50 gating was 
not significantly associated with beta bandpower in patients or controls.  
 Working Model of Susceptibility to Smoking and Nicotine Dependence 
 The final hypothesis tested was that variables previously presumed to underlie 
vulnerability to nicotine use including diagnosis, family history of smoking, and 
electrophysiological functioning would predict smoking behavior. Hypothesis 3b was 
tested using binary logistic regression first to predict history of ever smoking, 
followed by current smoking. In the first model, predictor variables including 
diagnostic group, family history of ever smoking (which includes both current and 
former smokers), log transformed power in the beta and gamma frequency bands, and 
P50 ratio were entered simultaneously to test the overall predictive value of the 
model; beta coefficients were examined to determine the significance of each variable 
in predicting ever smoking. For the resting EEG data, log transformed power for 
electrode sites Cz and Fz were averaged together to create one variable pe frequency 
band. This first model was significant (R2 = 0.16, χ2 = 11.59, p = 0.04) and accurately 




smoking). Beta coefficients for diagnosis (β = 1.65, p = 0.016) and family history of 
ever smoking (β = 1.20, p = 0.03) were the only significant predictors. The regression 
analysis was repeated utilizing relative current smoking as a predictor variable, rather 
than family history of ever smoking; the overall model was significant (R2 = 0.197, χ2 
= 14.72, p = 0.01) and accurately classified 69.7% of ever smokers. Diagnostic group 
(p = 0.009) and family history of current smoking (p = 0.01) were both significant 
predictors in the model.   
 The same regression models were tested again to predict current smoking 
among probands. The overall model was not significant (R2 = 0.128, χ2 = 9.16, p = 
0.10) when family history of ever smoking was used as a predictor (p = 0.37) 
although the beta coefficient was significant for diagnostic group (p = 0.016). Again, 
electrophysiological data did not have significant predictive power in the logistic 
regression model.  The model improved and was significant in predicting current 
smoking status among probands when family history of current smoking was entered 
as a predictor instead of family history of ever smoking. The logistic regression 
model including diagnostic group, relative current smoking, log transformed power in 
the beta and gamma frequency bands, and P50 ratio correctly classified 70.1% of 
cases overall (R2 = 0.192, χ2 = 14.24, p = 0.01). Diagnostic group (β = 2.37, p = 0.01) 
and family history of current smoking (β = 1.90, p = 0.02) were both significant 
predictors while electrophysiological data remained non-significant.  
 Summary of Main Findings: Specific Aim 3 
 Electrophysiological activity measured during an evoked P50 gating paradigm 




patient non-smokers demonstrated impaired gating relative to control non-smokers, 
unexpectedly, overall diagnostic group differences in P50 performance appeared to be 
minimized due to current nicotine use; a significant disordinal interaction between 
diagnostic group and smoking status rendered main effects uninterpretable in thes 
analyses. Smoking status had an effect on resting EEG as well, such that resting 
activity appeared elevated in former smokers across alpha, beta, and gamma 
frequency ranges. The original study hypotheses were not supported, as beta power 
was not significantly aberrant with respect to diagnostic group or smoking status. 
While differences in beta power between current and former smokers approached 
statistical significance, group differences were significant in the gamma range. 
Greater amplitude responses in the P50 gating components were associated with 
greater power across the frequency spectrum, yet these relationships were statistically 
significant at the higher and lower ends of the frequency bands when examined in 
patient and controls respectively. Finally, a series of regression analyses suggested 
that having a schizophrenia-spectrum disorder and a family history of smoking are 
highly significant factors in predicting regular nicotine use. Diagnostic status and the 
familial (genetic and/or environmental) effects of smoking appeared more salient than 






Chapter 5:  Discussion 
This study aimed to characterize factors which putatively contribute to 
nicotine use and the development of dependence among individuals with 
schizophrenia. The literature to date indicates that increased rates of smoking, 
elevated levels of dependence on nicotine, aberrant smoking patterns, and low rates of 
quitting among smokers with schizophrenia are not effectively explained by 
sociodemographic factors or factors secondary to treatment. Rather, the relationship 
between smoking and schizophrenia may be more primary. This study sought to 
investigate mechanisms of increased vulnerability to smoking and nicotine 
dependence through three specific aims examining the individual and interacting 
effects of familial vulnerability factors, neurophysiological function, and cortical 
oscillatory activity. Based on the empirical literatures on schizophrenia and on 
substance use and addictions, hypotheses were formulated to examine smoking 
patterns relative to a diagnosis of schizophrenia, the effect of a family history of 
schizophrenia on the heritability of nicotine use, the relationship between oscillat ry 
activity in the beta frequency band of resting EEG and nicotine use, and the 
relationship among putative susceptibility factors in collectively predicting smoking 
and nicotine dependence.  
The study sample was composed of four groups including outpatients with 
schizophrenia or schizoaffective disorder, first-degree relatives of patient index 
probands, healthy comparison control subjects from the community, and first-degree 
relatives of control probands. Comparison controls were recruited from the 




in preliminary statistical analyses, there were no significant differences between 
proband groups with respect to age, sex, or race/ethnicity. Lifetime prevalence of 
comorbid drug or alcohol abuse and dependence in the patient proband group (38.5%) 
was elevated relative to the control proband group (24.4%). The rate of substance 
abuse within patients was consistent with the rate of co-occurring substance use with 
schizophrenia reported in the literature (40 to 50%; Blanchard et al., 2000). The rate 
of family history of schizophrenia-spectrum disorder (14.4%) in the sample of patient 
probands is consistent with empirical findings from family studies indicating rates of 
psychotic disorder, schizophrenia-spectrum personality disorder, and schizophrenia 
between 9% and 15% among first-degree relatives of schizophrenia probands (Glatt, 
2008). The patient sample in this study appeared adequately representative of the 
larger schizophrenia population.  
Smoking and Nicotine Dependence 
 Sample Characteristics 
The first specific aim of the study was to characterize past and present 
smoking behaviors and level of nicotine dependence in the sample to examine the 
relationship between smoking history and vulnerability for schizophrenia. This 
relationship was examined in two ways, first by comparing rates of smoking and level 
of dependence between proband groups, and second by calculating heritability 
estimates for smoking. As expected, history of smoking significantly varied between 
groups, whereby patient probands were more likely to have ever smoked (68.1%) and 
were more likely to be current smokers (56%) than community controls (45.9% and 




to 23%, the rate of current smoking in the healthy controls was on par with population 
rates, and patient proband reports of current smoking were significantly elevated in 
comparison.  
When proband groups were compared with respect to never, former, and 
current smoking, individuals drawn from the general population appeared more likely 
than patients to initiate smoking without becoming addicted, or were more likely to 
have been able to quit. This observation is given by the percentages of former 
smokers in each proband group; in addition, a significantly greater proportion of ever 
smokers were former smokers in the sample of healthy controls than in the patient 
proband group. Consistent with these findings and in support of the hypothesis that 
smokers with schizophrenia are more likely to develop dependence on nicotine, 
patient smokers reported greater levels of nicotine dependence on the Fagerstrom 
Test for Nicotine Dependence (FTND total score) than comparison control smoker 
when both a history of smoking and current smoking were considered. Also 
compared dichotomously based on FTND total item endorsement, patient smokers 
were more likely to be classified as nicotine dependent than control smokers when 
ever smokers (current and former) and only current smokers were considered. The 
mean number of smoking years reported by patient smokers was relatively greater 
than smoking years reported by the comparison controls, although the statistical 
significance of this difference depended on the inclusion of those individuals who 
reported current substance use; regardless, this difference yielded an effect size in the 
small range. Thus, despite reporting a similar number of years of smoking, smoker 




population to have a history of persistent smoking, more likely to become nicotine 
dependent, and report greater levels of nicotine dependence than other smokers.  
Given that propensity towards nicotine dependence is hypothesized to be 
associated with biological substrates of schizophrenia (e.g. overlapping genetic 
vulnerabilities), elevated rates of smoking were expected among first-degree relatives 
of schizophrenia probands in comparison to first-degree relatives of healthy controls. 
Preliminary investigation of rates of smoking among participating family embers 
did not lend support to this hypothesis.  The rate of current smoking among first-
degree relatives was actually relatively greater among participating parents and 
siblings of controls (18%) and closer to general population rates than the rate of 
current smoking reported among participating parents and siblings of patient 
probands (13%). 
 Heritability Analyses 
A more rigorous analysis of the familial liability towards nicotine use entailed 
calculation of heritability estimates based on a polygenic model, taking into account 
both age and sex as covariates, for each group. Review of the literature to date on the 
heritability of smoking did not yield reports of heritability estimates specific to 
populations with schizophrenia. This study is therefore unique in providing this 
report. Heritability estimates were high for patients and controls with similar values 
between groups for history of ever smoking (approximately 0.90). Interestingly, the 
heritability estimate for current smoking in the patient group remained high and was 
significant while the same calculation yielded a much lower value when current 




smoking in the control group was not statistically significant. Although the 
heritability estimate for current smoking in the control group is within a valid r nge, 
the lack of statistical significance and within group difference in values between ever 
and current smokers suggests that current smoking was likely a less accurate 
reflection of the heritability of smoking in this sample. The between-group differenc  
may have been a result of the likelihood that, in the sample of healthy controls, 
smokers were more likely to have smoked in the past and few reported currently 
smoking. In contrast, rates of past and present smoking were high in the patient 
group, thus appearing to provide equally valid assessments of propensity towards 
nicotine use.  
The heritability estimate for current smoking may, in general, be a better 
estimate of the genetic contribution to nicotine dependence. The group classified a  
ever smokers is a more heterogeneous group, composed of both current and former 
smokers and may include individuals who were exposed to nicotine (i.e. initiated use) 
but failed, for myriad possible reasons, to develop a longstanding pattern of use 
indicative of nicotine addiction. Prior studies report total heritability estimates for 
initiation and progression to nicotine dependence to be between 60 and 70% (Kendler 
et al., 1999; Sullivan & Kendler, 1999; True et al., 1997) with some estimates of 
heritability for persistent smoking as high as 84% (Li, 2006). The findings of 
significant heritability for smoking history in this study, and for current smoking in 
particular, are consistent with published reports suggesting a large familial 
component to persistent nicotine use. While environmental and genetic factors 




suggest that genetic factors play a larger role in conferring vulnerability towards 
continuing nicotine use and the progression towards dependence (Maes, Sullivan, 
Bulik, Neale, & Prescott, et al., 2004; Sullivan & Kendler, 1999).  
Ideally, this study would have also utilized the total score on the FTND to 
calculate heritability for nicotine dependence directly, rather than on relyi g 
dichotomous variables relating to smoking history and on a differentiation between 
ever and current smokers to approximate dependence. The number of first-degree 
relatives of control probands who participated and completed the FTND was too 
small to provide an accurate evaluation or point of comparison for the schizophrenia 
group.  However, limitations due to the psychometric properties of the FTND may 
constrain the utility of this measure, particularly in interpreting heritabil y estimates 
for nicotine dependence. Retrospective versus current reporting biases in former and 
current smokers may impact the reliability of FTND nicotine dependence data. Prior 
research utilizing DSM criteria for diagnosing nicotine dependence and/or a cut-off  
score of  4 or greater on the FTND have  provided heritability estimates in the range 
of 0.40 to 0.70 (Gelernter et al., 2007; Saccone, Hinrichs, Saccone, Chase, & 
Konvicka, et al., 2007; Uhl, Liu, Drgon, Johnson, & Walther, 2007). Specific genes 
have been investigated and found to be significantly associated with nicotine 
dependency including those related to nicotine receptors themselves such as 
CHRNA5 (Saccone et al., 2007) and CHRNA4 (Li, Beuten, Ma, Payne, & Lou et al., 
2005), nicotine metabolizing enzymes, dopamine receptors, and GABA receptors 
including GABAB2 (Beuten, Ma, Payne, Dupont, & Crews, et al., 2005) and 




history and measures of nicotine dependency converge in suggesting a significant 
genetic contribution to persistent smoking and the development of nicotine addiction. 
The findings from this study, particularly in the schizophrenia proband group, add to 
this existing literature.   
In sum, the hypotheses for the first specific aim were partially supported. 
Based on rates of former and current smoking in the patient and control groups in this 
study, the data presented here demonstrate a pattern of more persistent nicotine use 
and greater dependence among those with schizophrenia relative to non-psychiatric 
comparison controls drawn from the general population. Persistent smoking was also 
demonstrated to be highly heritable. Analyses failed to yield results consistent wi h 
the hypothesis that smoking would be more familial in those affected by 
schizophrenia. Given that probands were recruited to match on demographics and 
geographical location, and that groups were statistically similar when group 
composition was compared, sociodemographic factors are not likely accountable for 
the differences between groups observed here. Additionally, participants in both 
groups reported histories of drug or alcohol use and individuals with current 
substance use (past 6 months) were excluded from the study sample. Rates of 
persistent smoking in both groups and the elevated prevalence of current nicotine use 
and dependence in the patient group did not appear to be explained by co-occurring 
substance use. However, this study sought to utilize electrophysiological measures 
that appear to relate to a vulnerability towards alcohol and other substance use to test 





Electrophysiological Function and Smoking 
Quantifying brain oscillatory activity is a tool that has been used to investigate 
cortical pathologies underlying a variety of psychiatric conditions. In the addictions 
literature, elevated power in the beta band of resting EEG has demonstrated 
significant predictive utility with respect to behavioral outcomes; though initial 
reports focused on predicting alcohol use, findings have been extended to include 
prediction of illicit drug use as well. Although the precise significance of excitatory 
and inhibitory dysregulation, as discussed by Begleiter, Porjesz and colleagues, is not 
known, cortical hyperarousal may confer vulnerability to substance use or the 
development of physiological dependence, or may result in poor modulatory control 
over substance use behaviors resulting in persistent use and addiction. In a separate
literature, altered cortical activity observed in schizophrenia has been linked to 
aberrant information processing at the neurophysiological (i.e. sensory gating) and 
neuropsychological (arousal/attentional processes) levels. Altered cortical activity 
may also have implications for behavioral abnormalities, such as those related to 
addictions. The second specific aim of this study sought to characterize the 
relationship between EEG power and addiction to nicotine among schizophrenia and 
healthy comparison control probands.  
 EEG and Smoking Status 
The hypotheses associated with the second specific aim were mostly 
unsupported. Repeated measures ANOVA failed to find diagnostic group differences 
in power for the alpha, beta, and gamma frequency bands and, contrary to 




However, analyses did reveal interesting associations between power in the gamma
frequency band and smoking status whereby former smokers demonstrated greater 
mean bandpower in the gamma band than current smokers. This pattern was generally 
observable in the alpha and beta ranges as well, with effect sizes in the small to 
medium range, but a comparison of means yielded statistically significant results in 
the higher frequency range of resting EEG only. The main findings were unaffected 
by differences in medications such as clozapine or benzodiazepines.  
Although an association between beta power and nicotine dependence was 
plausible to hypothesize given established findings relating elevated beta power to 
alcohol and other substance use, mechanisms conferring vulnerability to nicotine 
dependence may be different. In distinguishing factors relating to nicotine 
dependence, prior studies of susceptibility to substance use have been confounded 
due to the common co-occurrence of nicotine and other substance abuse or 
dependence. Conclusions about the relationship between nicotine and beta frequency 
activity at rest have thus not been established. As suggested by the data in this study, 
there may be a unique association between nicotine use and electrophysiological 
activity at high frequency bands; this unique association may be limited to gamma 
frequency activity, or may potentially include beta as well.  
Given that current and former smokers were distinguished by significantly 
different gamma power and that differences in beta power approached, but failed to 
reach, statistical significance (p = 0.07), the data from this study might be interpreted 
as indicating alterations higher frequency range activity more broadly, rather than 




between beta power and nicotine use may be attributable to the methodologies 
employed, i.e. the wide range in which beta activity was defined in this study 
compared to the frequency ranges defining beta in other studies. Additional analyses 
examining a narrower range of beta activity, limited to the upper end of the frequency 
spectrum, might help to clarify the role of beta in conjunction with gamma activity as 
conferring susceptibility to nicotine use.         
The acute effect of nicotine on EEG activity is characterized by a shift 
towards higher frequency band activity and has been reported to effect the beta band 
(Domino, 2003; Kadoya, Domino, & Matsuoka, 1994). The pattern of EEG activity 
relative to smoking status in this study may be considered for interpretation more 
broadly. Since subjects were not under the direct influence of nicotine at the time of
testing, lower power in high frequency ranges (i.e. beta and/or gamma) might be 
expected among current smokers, constituting a withdrawal effect. A dose-dependent 
increase in EEG activity and concurrent improvement in cognitive processing has 
been documented with acute nicotine administration, as well as decrements in 
cognitive functioning and decreased activity with short-term or overnight nico i e 
abstinence (Kadoya et al., 1994). Electrophysiological withdrawal effects have been 
reported to occur between 6 and 15 hours after nicotine use (Domino, 2003) or within 
as early as 4 hours after smoking (Heishman, 1999). Participants in this study were 
instructed to refrain from smoking only 30 minutes prior to testing. Nonetheless, 
abstinence effects should not be ruled out.  
When participants were classified dichotomously for nicotine dependence, 




Correlational relationships between FTND Total score and power were not, however, 
significant. Although power may not vary as a function of dependence severity, 
dependent smokers may consume more nicotine than non-dependent smokers; given 
evidence for a relationship between plasma concentrations of nicotine and cortical 
activity, altered EEG activity among current smokers may be attributed to short-term 
nicotine consumption (or lack thereof). If not a withdrawal effect, decreased activity 
among current smokers may be interpreted as a baseline low level of activity, 
reflective of some neuroelectric deficit, that is subsequently boosted by nicotine wi h 
smoking. This remains hypothetical.  
Alternatively, relatively elevated power among former smokers might reflect a 
long-term effect of past nicotine use. The prolonged effects of nicotine exposure on 
EEG have not been clearly defined in the literature, yet there is some evidence to 
suggest persistent brain changes in former smokers; Neuhaus and colleagues (2006) 
documented dysfunctional activation of frontal lobe networks in long-term nicotine 
abstainers (Neuhas, Bajbouj, Kienast, Kalus, & von Haebler, et al., 2006). The pattern
of activity in never, former, and current smokers in this study may suggest that past 
and present nicotine use results in prolonged cortical arousal and that current smokers 
may have been undergoing acute withdrawal at the time of testing, resulting in 
marked decreases in cortical activation. Findings reported by Domino (2003), that 
nicotine enhances brain function through both reversal of withdrawal and an 
additional stimulatory effect on EEG, supports this interpretation alongside findings 
reported by Neuhaus and colleagues (2006), that nicotine may have a prolonged 




the present study is not longitudinal and time of last cigarette was not assessed, 
conclusions about alterations in power among former or current smokers, as being 
attributable to an underlying pathophysiological process conferring vulnerability to 
dependence, a stable effect of long-term use, or an acute effect of nicotine withdra al 
remain speculative. 
 EEG and Schizophrenia 
There is ample evidence reported in the literature that schizophrenia is 
associated with aberrant EEG activity. The lack of diagnostic differences observed 
here was unexpected. The majority of research on quantitative EEG power spectra
has reported augmented lower frequency range activity (delta and theta) and lower 
alpha band power when at rest (Clementz et al., 1994; Sponheim et al., 2000). There 
is some evidence supportive of increased beta frequency power as well (Gross, 
Joutsiniemi, Rimon, & Appelberg, 2006; Whitford, Farrow, Rennie, Grieve, & 
Gomes et al., 2007). Irregular patterns in electrophysiological functioning do ot 
appear to be epiphenomena associated generally with psychopathology. Aberrant 
spontaneous lower range frequency activity found in schizophrenia is thought to be 
associated with poor modulation of arousal and attention, and may be associated with 
the presence of neuroanatomical abnormalities and negative symptoms (Sponheim et 
al., 2000). Gross and colleagues (2006) reported a specific association between 
elevated beta frequency activity, as measured at a fronto-central site t rest, and 
ratings of psychomotor poverty in schizophrenia.  
Whitford and colleagues (2007) presented longitudinal data demonstrating an 




schizophrenia patients and increases in fronto-partietal EEG power in slow wave and 
beta frequency bands over time. Interestingly, the authors note that grey matt r 
damage, as may be found in patients with traumatic brain injury, has been associated 
with increases in slow wave power and decreases in beta power, thus suggesting that 
a unique association exists between grey matter volume and electrophysiological 
functioning in schizophrenia (Whitford et al., 2007). Elevations in EEG power in 
higher frequency bands at rest might indicate abnormal neural synchrony, which is 
thought to be related to information processing abnormalities manifested as cognitive 
disorganization and reality distortion (Whitford et al., 2007).  Of note, the beta 
frequency band in the Whitford et al. study (12.5 to 34.5 Hz) extended into the 
frequency range defined as gamma in this study (30 to 50 Hz); although this overlap 
is fairly minimal, caution in interpreting EEG data with respect to functional 
distinctions between frequency bands appears warranted. Prior interpretations of 
aberrant resting bandpower have, however, been based on such functional 
distinctions.  
In a recent investigation of baseline spontaneous and stimulus-evoked cortical 
activity however, schizophrenia patients did not demonstrate aberrant resting 
oscillatory activity in any frequency band examined, but did evidence significant 
reductions in frontal gamma oscillations, relative to non-psychiatric controls, in 
response to direct stimulation (Ferrarelli, Massimini, Peterson, Riedner, & Lazar, et 
al., 2008). Other investigations of higher range frequency activity in EEG have found 
substantial evidence for decreased entrainment of EEG oscillations in the beta and 




of induced or stimulus-evoked beta and gamma band activity (Kwon, O’Donnel, 
Wallenstein, Green, & Hirayasu, et al., 1999; Light et al., 2006; Spencer, Nestor, 
Perlmutter, Niznikiewicz, & Klump, et al., 2004). Thus, while the extant literature is 
inconclusive with respect to aberrant activity at higher frequencies while at rest, here 
is more sufficient evidence to suggest that schizophrenia is associated with deficient 
evoked activity in higher frequencies in response to stimulation.   
In addition to irregular patterns in spontaneous cortical activity, aberrant 
stimulus-evoked higher range frequency activity appears to be associated with altered
processing of sensory stimuli, particularly in the auditory domain, and is thought t 
relate to impairments of local GABAergic inhibitory interneurons (Kwon et al., 
1999). Impairment in the ability to generate gamma oscillations is hypothesized to 
indicate dysfunction in thalamacortical circuits which underlie inhibitory processing 
deficits, such as those found with sensory gating paradigms. However, Hong and 
colleagues (2008) reported significant contributions of beta band activity to 
impairments of sensory gating with the presentation of auditory stimuli.  Additional 
alterations in synchronous gamma oscillatory activity, indicating poor neural 
integration in thalamic and cortical neuronal circuits, may relate to alterations in 
perceptual binding (i.e. encoding of sensory information) integral to accurate 
cognitive processing. As mentioned by Whitford and colleagues (2007), higher 
frequency range abnormalities, such as those in the gamma band, may also have 
implications for positive and disorganized symptoms of schizophrenia (Kwon et al., 




Given the substantial evidence for early sensory and higher order cognitive 
processing impairments found in schizophrenia, as well as evidence for aberrant 
oscillatory activity, the lack of diagnostic differences in resting EEG was unexpected. 
However, these results are consistent with the findings of Ferrarelli et al. (2008) with 
respect to the lack of diagnostic differences in EEG activity at rest and the 
dissociation reported between oscillatory activity measured at rest and aberrant 
evoked oscillatory activity in response to sensory stimuli. The unique association 
between beta activity and P50 gating performance in schizophrenia reported by Hong 
et al., 2008 were also within the context of stimulus-evoked activity and not cortical 
activity at rest. Data reduction procedures in this study were, however, limited to 
examining resting EEG activity from 8 to 50 Hz, segregated into broad frequency 
ranges representative of alpha, beta, and gamma activities. Lower frequency power in 
the delta and theta bands was not examined, and a more refined analysis of power 
data within each frequency band may have yielded more informative results with 
respect to diagnostic differences.  
For example, beta may be further segregated into beta 1, beta 2, and beta 3; 
given that the implications of low beta, coupled with power in the alpha band may 
have different correlates in schizophrenia than high beta, coupled with power in the 
gamma band, subsequent analyses may consider refining the data reduction 
techniques. Additionally, the gamma frequency band is broad and functional 
correlates, such as those found in this study, may be further examined with respect to 
more narrowly defined frequency ranges. For example, reduced auditory stimulu -




40 Hz, whereas non-significant differences in power were found between 
schizophrenia patients and controls with frequency stimulation at 20 and 30 Hz. As 
mentioned prior, elevated resting EEG power reported by Whitford and colleagues 
(2007) was found in a broad frequency band defined by the authors as beta, which 
corresponded to high beta and low gamma frequencies as defined in this study. Thus, 
the findings of power abnormalities across the frequency spectrum in schizophrenia 
may be subject to significant methodological variance. Given the relationship 
between reduced evoked gamma activity and cognitive processing deficits, and the 
interaction between nicotinic and GABAergic neurotransmission in modulating 
inhibitory neuronal processes, the implications of the association found between 
reduced gamma power at rest and smoking status is open for interpretation.  
The functional implications of cortical activity at rest were further 
investigated in this study by examining the relationship between frequency ba d 
power and P50 gating.  Although schizophrenia is commonly associated with poor 
P50 suppression, the lack of significant main effect of diagnostic group for P50 gating 
in this study appears attributable to smoking status. When never smokers were 
considered alone, patients with schizophrenia in this study demonstrated poor P50 
suppression relative to comparison controls. The magnitude of the difference betwe n 
patient and control non-smokers yielded an effect size in the medium range, 
supporting prior findings of deficient gating in schizophrenia. There was a significant 
disordinal interaction between diagnostic group and smoking history whereby current 
smokers demonstrated similar P50 ratios to non-smokers in the patient group while 




group. A closer examination of the effect of smoking on sensory gating between 
groups demonstrated significant differences in P50 performance between current and 
former smokers, and between current and never smokers in the control group, with 
similar P50 ratios among never and former smokers. These significant contrasts were 
not observed in the patient group.  
In addition to the differential effect of current smoking on P50 gating 
performance across groups, it is noteworthy that even among patient probands who 
were former or never smokers, patient P50 ratios were lower than might be expected 
as given by prior reports in the literature. Similarly, among controls who currently 
smoke or who have ever smoked, the P50 ratio might be considered aberrantly high. 
Recent meta-analytic findings reported by Patterson and colleagues (2008) 
documented significant variability in the range of results reported across different 
research groups, with mean P50 ratios of 0.799 ± 0.243 for patients with 
schizophrenia and 0.388 ± 0.153 for non-psychiatric controls. Other reviews of P50 
gating also note methodological variance and significant heterogeneity of results 
reported in the literature; de Wilde and colleagues (2007) indicate that assessment of 
smoking status is inconsistent across studies and is thus one such variable that likely 
contributes to variability in findings (de Wilde, Bour, Dingemans, Koelman, & 
Linszen, 2007).  
Given that diagnostic groups were stratified and compared using smoking 
status as a between groups variable in this study, the deviations from expected P50 
values observed here may not be abnormal. Rather, these data underscore the 




by de Wilde and colleagues. Considering the pattern of P50 data among patient and 
control non-smokers, the dataset presented here may be considered an adequate 
representation of P50 performance in the schizophrenia and general non-psychiatric 
populations.  The significance of considering smoking status as a between groups 
variable in future studies is highlighted by these data. 
In addition to the effects of nicotine on sensory gating, patient and control 
proband groups were further distinguished by the relationships observed between 
electrophysiological measures. Brain responses to auditory stimulation utilzing the 
P50 paradigm were analyzed by examining correlates of S1 and S2 amplitudes 
separately. S1 amplitude may be considered representative of general activity,
whereas S2 is expected to be decremented due to the neural inhibitory mechanism. 
Overall, greater amplitude responses were associated with greater power across the 
frequency spectrum. In patients, power in the gamma frequency was significantly 
correlated with response amplitudes to both auditory stimuli whereas in the control 
group, amplitudes of responses to auditory stimulation were significantly correlated 
with lower frequency activity in the alpha frequency band. Thus in the control group, 
general indicators of arousal, S1 and alpha power, were expectedly related. In the 
patient group, relationships between higher resting frequency activity and evoked 
responses were limited to smokers, as the correlations between amplitudes and power 
were significantly reduced when never smokers were considered alone. These results 
again underscore the importance of assessing smoking status when studying 




Relationships between electrophysiological indices were not as expected and 
the results did not support the hypothesized relationship between beta power and P50 
gating as presented in the third specific aim. Additional analyses may further examine 
the relationship between power in fast resting EEG and other indices of neural 
processing by segregating spectral power into more distinct frequency bands within 
the beta and gamma ranges. It appears that smoking is uniquely related to 
electrophysiological activity in probands with schizophrenia and that smoking status
should be assessed in any study of information-processing dysfunction in this 
population. 
 Predictors of Smoking 
In addition to characterizing relationships among electrophysiological 
variables in relation to diagnostic and smoking status, the third specific aim soughtt  
examine the collective predictive value of all relevant putative susceptibility factors 
for nicotine use. Logistic regression was utilized to test the significance of diagnostic 
group, family history of smoking, and cortical electrophysiological activity, including 
stimulus-evoked P50 gating and higher frequency oscillatory activity (12 to 30 Hz) 
measured at rest, to predict smoking status. Among all regression models tested, 
diagnostic group and family history of smoking were the only significant predictors 
of smoking status, considering both ever and current smoking. Family history of 
current smoking appeared to be a more consistent predictor of proband smoking than 
family history of ever smoking. Given that the group of ever smokers is more 




able to quit, whereas the group of current smokers represents those for whom 
smoking has been more persistent, this result seems logical.   
Notably, the logistic regression model including diagnostic group, family 
history of current smoking, and electrophysiological data correctly classified 70.1% 
of cases when current smoking was predicted and 69.7% of cases when ever smoking 
was predicted. The lack of predictive value of electrophysiological data in these 
models is difficult to interpret due to methodological constraints and the potential 
confounding effects of the interactions between nicotine use, diagnostic group, and 
electrophysiology. However, these data clearly underscore the important roles hat 
family history of smoking and a diagnosis of schizophrenia play as susceptibility 
factors to nicotine use and dependence.  
 Summary of Findings: Specific Aim 3 
In summary, schizophrenia appears to be uniquely related to smoking 
behavior and nicotine dependence. Susceptibility to smoking in general is strongly 
impacted by familial patterns of smoking. Prior research and the present findi gs 
together implicate both environmental and genetic factors in influencing smoking 
initiation and persistent patterns of nicotine use are likely influenced more heavily by 
genetic factors. A diagnosis of schizophrenia and a familial predisposition to smoking 
are, together, significant predictors of persistent patterns of nicotine use. In th  
present study, when data were subjected to statistical analysis, diagnosis and family 
history best captured what may be characterized as an underlying (i.e. 
neurobiological) vulnerability to nicotine dependence, rather than circumscribed 




The nature of the relationship between nicotine use and various aspects of 
electrophysiological functioning in this study is difficult to define due to evidence 
that nicotine differentially influences cortical activity in persons with schizophrenia 
relative to non-psychiatric controls. In this study, non-smokers with schizophrenia 
demonstrated relatively deficient P50 gating, as might be expected based on the 
extant literature. Among patients who currently smoke, P50 gating performance w s 
within a range typically found in the non-schizophrenia population, while controls 
who currently smoke demonstrated aberrant gating performance. Across groups, 
gamma power at rest was significantly different between former and current smokers, 
but unique relationships between stimulus evoked activity and resting 
electrophysiological activity were found when patients and controls were considered 
separately and when further examined with respect to smoking status. In patients with 
schizophrenia, gamma power was significantly correlated with amplitude of 
responses to auditory stimuli in the P50 paradigm among current smokers but not in 
never-smokers. While high frequency activity at rest was significantly associated with 
responses to sensory stimulation in smokers with schizophrenia, low frequency 
activity (i.e. alpha bandpower) was associated with level of response to auditory 
stimulation in the sample of non-psychiatric controls. Due to the few number of 
control smokers with P50 data available, differential associations in smokers and non-
smokers could not be distinguished within this group. 
Although this study sought to characterize the relationship between resting 
EEG activity in the beta frequency band and nicotine use, strong associations were 




predicting alcohol dependence and, perhaps vulnerability to substance use more 
generally, the lack of association with nicotine use in this sample was unexpected. 
Given prior evidence that abnormal stimulus evoked activity in both the beta and 
gamma frequency bands have been reported to be associated with indices of 
neurophysiological functioning among individuals with schizophrenia (e.g. Hong et 
al., 2008), a more refined investigation of resting EEG activity (e.g. higher frequency 
activity within the beta range) may be considered for future studies. With regard to 
future research in general, given the unique relationship between electrophysiological 
activity and smoking in persons with schizophrenia, future studies are wise to 
consider smoking status as a variable of significance which should be accounted for 
methodologically and statistically. 
Summary of Limitations and Future Directions 
 Limitations of the Research Sample 
 The study data were consistent with prior findings that rates of smoking and 
nicotine dependence are aberrantly high in persons with schizophrenia compared to 
non-psychiatric controls from the general population. The study data presented here 
suggest that in addition to demonstrating greater levels of nicotine dependence, 
persons with schizophrenia who present with a history of smoking are less likely than 
smokers from the general population to have successfully quit. Despite these 
informative findings, the low number of current smokers in the control proband group 
and the low number of former smokers in the schizophrenia proband group posed 
limitations on additional analyses to differentiate those who have been exposed to but 




able to quit. With a larger sample including more former smokers, factors 
differentiating former from never smokers and from current smokers might yield 
interesting results. Patterns of smoking over time (e.g. number of quit attempts, 
duration of smoking before quitting, level of past nicotine dependence) might be 
compared in future studies of former and current smokers.  
 A larger study sample would also allow for better characterization of familial 
factors affecting smoking in patients with schizophrenia relative to non-psychiatri  
controls. A greater number of first-degree relatives in the control group, for example, 
may have allowed for a better characterization of the heritability of current smoking. 
Nevertheless, the data collected did allow for the calculation of heritability estimates 
for smoking history for schizophrenia and control group participants. Estimates wer  
high and statistically significant, consistent with prior reports of significant genetic 
contributions to persistent smoking. Although direct comparisons were not made, 
there appeared to be no appreciable difference in the heritability estimates between 
patients and controls when history of ever smoking was considered. Thus, the familial
factors that contribute to smoking in families with a history of schizophrenia and in 
those without are likely to be similar.  
 It should be noted that the heritability estimates reported here demonstrate 
familial relationships between smokers. These estimates signify the additive effects of 
genetic and environmental factors and should not be interpreted as indicating genetic 
contributions alone. Given this inherent limitation, recruitment of a greater number of 
probands and family members with reported levels of nicotine dependence on the 




characterization of the familial effect on nicotine use patterns. However, limitations 
of the FTND should be noted here as a caveat for future analyses. The reliability of 
the FTND has been demonstrated in prior studies as being adequate (0.61); in this 
study sample, the reliability was lower, a = 0.503 for current smokers and a = 0.507 
for ever smokers. Other measures of nicotine dependence may demonstrate greater 
reliability. With respect to future analyses, potential reporting biases for past versus 
current smoking may impact the validity and reliability of the FTND. Retrospective 
assessment of nicotine dependence may be biased due to inaccurate recall or, due to a 
tendency to recall and report smoking patterns consistent with a period of heaviest 
use. Current smokers’ patterns of use may not, however, reflect a period of heaviest 
use. Assessment of nicotine dependence among ever smokers, including both current 
and former smokers, may thus require specification of reporting parameters which 
may artificially elevate estimates of nicotine dependence, in order to impr ve the 
reliability of the measure.   
 Limitations of the Methodology  
 Aside from sampling limitations, methodological limitations with respect to 
differentiating between alpha, beta, and gamma power should be noted. Based on the 
research question at hand, resting EEG was analyzed in three frequency bands as 
defined by the general research literature. A re-examination of the data might include 
investigation of lower frequency activity in the delta and theta bands. In the absence 
of external stimulation, low frequency EEG activity is dominant relative to high 
frequency activity. Augmented low frequency activity has commonly been reported 




lower frequency bands in the analyses would have provided a useful control in 
statistical comparisons of higher frequency activity between patients and healthy 
comparison subjects, as well as provided a point of comparison with data collected in 
other electrophysiological studies. Similarly, the monopolar electrode sites chosen for 
analyses were based on the literature suggesting that frontal and central leads yield 
the most consistent results with respect to beta power and alcohol dependence 
vulnerability. In expanding the frequency range in which to investigate susceptibility 
to nicotine use, additional electrode sites may also need to be considered.  
The main effect of smoking status for beta power in the current sample 
approached statistical significance with a p value of 0.07. Given this statistical trend 
and that the hypotheses described within the second specific aim were unsupported in 
favor of an association with gamma power, future examination of this data might 
utilize a more refined analyses of frequency activity within the beta band. 
Electrophysiological studies of beta power in relation to susceptibility to alcoho  
dependence (e.g. Rangaswamy et al., 2002) have divided the beta band into three 
frequency ranges, beta 1 (12.5 to 16 Hz), beta 2 (16.5 to 20 Hz), and beta 3 (20.5 to 
28 Hz). Although Rangaswamy and colleagues (2002) reported elevated mean log 
beta power across the beta frequency band in relation to alcohol dependence, such 
distinctions might prove useful in studying nicotine dependence and would add to the 






The lack of diagnostic differences in resting EEG power demonstrated in this 
study does not lend support to the hypothesis that this measure of cortical activity
indexes processes contributing to susceptibility for nicotine use, thereby explaining 
aberrant rates of smoking in patients with schizophrenia. These data do, however, 
demonstrate that nicotine use significantly impacts cortical activity and sugge t that 
both prolonged and acute effects may be observed. As this study was a preliminary 
investigation of the relationship between power in resting EEG and nicotine use with 
respect to a diagnosis of schizophrenia, statistical analyses were limited to 
comparisons of group differences and examination of cross-sectional relationships 
among variables. The larger research question upon which this study was based is one 
that is more causal in nature. That is, does aberrant cortical activity among 
individuals with schizophrenia have implications with regard to persistent nicotine 
use via nicotine’s impact on neurobiological substrates associated with information-
processing impairment?  
Based on research in behavioral genetics and cognitive neuroscience, 
aberrantly high rates of persistent smoking and levels of nicotine dependence among 
persons with schizophrenia, as demonstrated here, might be explained in part by the 
unique remediating effects of nicotine on neurophysiological and neurocognitive 
impairments. These study data support the assertion that nicotine affects individuals 
with schizophrenia and non-psychiatric smokers differently and may suggest that 
nicotine has a prolonged effect and short-term effect on cortical activity, with acute 




presented here also support evidence for the additive genetic and environmental 
impact that a family history of smoking contributes in predicting nicotine use in 
addition to diagnosis.  
Due to the interacting effects of nicotine and electrophysiological function 
described in this study, together with the limitations of the study sample, the 
independent contributions of electrophysiological abnormalities and diagnosis to 
smoking, prolonged use, and the development of nicotine dependence could not be 
distinguished. Given the unique relationships reported and discussed herein, future 
studies might be implemented to (1) better distinguish between indices of 
electrophysiological function, utilizing both resting and stimulus-evoked paradigms,  
(2) relate putative susceptibility factors, whether diagnostic or electrophysiological in 
nature, to mediating processes and observable behaviors, and finally (3) better 
account for the confounding effects of acute nicotine use and smoking history in 
order to continue investigating factors underlying susceptibility to current nicotine 






 Neural Oscillations 
Neural oscillations are natural electrical fluctuations that occur spontaneously 
in the brain. Oscillatory activity is generated by ensembles of neurons through 
neurochemical processes, producing rhythmic activity at varying frequencies 
(Begleiter & Porjesz, 2006). Each frequency (measured in Hertz, or Hz) reflects a 
different order of brain activity (Niedermeyer, 1999).  Measurement of brain 
oscillations may be performed during resting states, without external stimuli triggers, 
or during states of activation whereby changes in oscillatory activity are locked to the 
timing of stimulus presentation and measured accordingly. Choice of methodology is 
dependent upon the research question.  
In general, the study of brain oscillations may elucidate the functional 
organization of neuroelectric activity (Begleiter & Porjesz, 2006), and thereby 
characterize important correlates of human information processing and cognition. 
Oscillatory activity can be assessed in terms of power, or the amount of activity in a 
given frequency band. Elevations in power within a frequency band may be indicative 
of a dominant state of electrical activity, which might bias the neural system towards 
a specific mode of sensory processing or mode of responding. Oscillatory activit  can 
also be assessed with respect to coherence and neural synchrony, which refer to the 
covariation in amplitudes and timing of oscillations recorded from different sites. 




ensembles across distributed neural populations and thus also affect information 
processing and influence modes of responding (Uhlhaas & Singer, 2006). Power and 
covariation of oscillatory activity, although both underlying coordinated brain 
function, may be studied independently and have demonstrated distinct behavioral 
correlates (Franken et al., 2004).  This study will focus on the power of oscillations 
across the frequency spectrum. Of particular interest is the power in the beta band of
resting EEG. 
In addition to describing modes of neural functioning, measures of oscillatory 
activity have been used in the field of behavior genetics. Variations in oscillatory 
activity are likely more proximal indicators of gene effects than complex neural 
processes, to which neural oscillations contribute. Human brain oscillations are highly 
heritable, with estimates ranging from 80 to 90% (van Beijsterveldt et al., 1996). 
Characterization of oscillatory power in resting EEG, reflecting a natural state of 
electrical activity, may yield fruitful results in identifying genes which contribute to 
more complex outcomes, such as cognitive performance and psychiatric 
symptomatology (Begleiter & Porjesz, 2006). A better understanding of gene variants 
associated with specific brain oscillations may yield important information bout 






 CNS Imbalance 
Begleiter and Porjesz (1999) propose that an inherited predisposition to 
developing alcoholism is represented by a general state of central nervous system 
(CNS) disinhibition or hyperexcitability. This innate CNS imbalance likely influences 
the occurrence of other disinhibitory conditions and is thus hypothesized to contribute 
to a number of externalizing disorders including drug abuse. The electrical outputas a 
result of this condition of cortical hyperexcitability can be measured using EEG 
techniques. One such technique is to assess brain oscillations, or natural electrical 
fluctuations, as they occur spontaneously in the brain. The presence of augmented 
beta and gamma oscillations (12 – 28 Hz and 29-50 Hz respectively) is thought to 
signify an activated state of neural activity, and is thus hypothesized to underlie th  
condition of CNS imbalance discussed by Begleiter and Porjesz. In brief, this 
imbalance is generated by the interplay between gamma amino butyric acid (GABA) 
and glutamate, the major inhibitory and excitatory neurotransmitters of the central 
nervous system. Neural excitatory activity, mediated largely by glutamate, is 
intimately connected with the activity of GABAergic interneurons, which serve to 
modulate and balance the feedforward excitatory signals between pyramidal cells 
through inhibitory feedback.  
A common feature of beta oscillations, in particular, is the involvement of 
networks of inhibitory interneurons. This is supported by a significant genetic linkage 
for the beta frequency in resting EEG reported as being located within a cluster of 
GABAA receptor genes on chromosome 4 (Porjesz et al., 2002). The networks of 




activity in the beta band appears to be a useful indicator of coordinated electrica  
activity and a measure of CNS balance. It is the elevation in beta power in resting
EEG, indicating relative disinhibition, which has demonstrated an association wi h 
































 Disinhibition and Schizophrenia 
Regulation of excitation and inhibition in the central nervous system is crucial 
for complex cognitive processes. Clinical features of schizophrenia include 
disturbances in cognitive processes such as impairments in attention, memory, and 
executive functions. These disturbances may be related to neural disinhibition. At a 
basic level, these cognitive processes rely on the coordinated activity of pyramidal 
neurons in the dorsolateral prefrontal cortex (DLPFC). In turn, coordinated activity 
requires the modulatory function of GABAergic inhibitory interneurons. Impairments 
in GABA-mediated inhibition in the DLPFC may provide a mechanism for the 
disturbances in working memory in individuals with schizophrenia. Consistent with 
this hypothesis are gene expression deficits and neuronal abnormalities in the DLPFC
affecting GABAergic activity in schizophrenia samples (see Lewis et al., 2005 for full 
review).  
In addition to cognitive dysfunction marked by poor inhibitory control in the 
prefrontal cortex, individuals with schizophrenia show significant neurophysiologica  
dysfunction associated with inhibitory interneuron activity.  Evidence suggests that 
inhibitory circuits in the hippocampus and thalamus, influenced by GABAergic 
interneurons, are particularly active in regulating sensory-driven neural processes 
such as sensory gating. Deficient P50 gating in schizophrenia is likely influenced by 
aberrant GABAergic interneuron activity in the hippocampus. Indeed, the expression 
of GABAergic receptors has been found to be reduced in post mortem hippocampal 
brain tissues of individuals with schizophrenia (Freedman et al., 2000). A reduction in 




Given the purpose of the proposed study, it is interesting to note the 
coexistence of α7 nicotinic acetylcholine receptors and GABAergic receptors in the 
hippocampus, and the reduced expression of both receptor types associated with 
schizophrenia. Given the association between beta band oscillatory activity and P50 
response (Hong et al., 2002; Hong et al., 2004) and the linkage between GABA genes 
and the beta band (Porjesz et al., 2002), it is possible that GABA receptor dysfunction 
and nicotinic acetylcholine receptor modulation of neural networks might together 
account for sensory gating deficits documented in schizophrenia. These findings are 
compelling in light of the high prevalence of smoking and high levels of nicotine 
dependence demonstrated in the schizophrenia population, and the relationship 
demonstrated between beta power and substance use. This study proposes to address 
the potential linkages between beta power, sensory information processing 












 Nicotine Dependence Assessment 
 
____ Have you ever been a smoker?   Y = Yes; N = No   
 
 If No, participant is a Non-Smoker, STOP. If yes, then proceed 
 
____ Are you currently a smoker?      Y = Yes; N = No 
 
 If No, how long ago did you quit? ______ (Specify days, weeks, months, or years) 
Fagerstrom Test for Nicotine Dependence (FTND) 
Directions: Please fill in the response with the appropriate number, then total the scores. If 
participant used to be a smoker but is not currently, please answer the following for when 
participant was a smoker. 
 
____ 1. How soon after you wake up do you smoke your first cigarette? 
  3 = within 5 minutes 2 = 6-30 minutes         1 = 31-60 minutes   0 = after 60 minutes 
 
____ 2. Do you find it difficult to refrain from smoking in places where it is forbidden (church, 
  library, cinema, etc)?  
1 = Yes 2 = No 
 
____ 3. Which cigarette would you hate most to give up? 
  1 = First one in morning 0 = All others 
 
____ 4. How many cigarettes/day do you smoke? 
  0 = 10 or less 1 = 11-20 2 = 21-30 3 = 31 or more 
 
____5. Do you smoke more frequently during the first hours after waking than during the res  of 
 the day? 
1 = Yes 0 = No 
 
____ 6. Do you smoke if you are so ill that you are in bed most of the day? 
  1 = Yes 0 = No 
 
______ Total Score  




____ 7. At what age did you begin to smoke? 
 
____ 8. At what age did you become a regular smoker? 
 
____ 9. How many years have you smoked cigarettes? 
 
____ 10. Have you ever tried quitting? (Y = Yes; N = No) 
 
____ 11. How many times have you quit for 24 hours or more? (State number in days) 
 
____ 12. What was the longest period you quit smoking? (Specify days, weeks, months, or 
years) 
 
13. If you have quit for 24 hours or longer, did you experience any of the following 
symptoms? (Check all that apply) 
 
A) craving for tobacco     ___ Yes ___ No  F) impatience             ___ Yes ___ No 
 
 
B) irritable, angry,       ___ Yes ___ No     G) disrupted sleep       ___ Yes ___ No 
     frustrated    
 
C) anxiety       ___ Yes ___ No  H) increased eating     ___ Yes ___ No 
 
 
D) trouble concentrating   ___ Yes ___ No   I) feeling drowsy ___ Yes ___ No 
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